US20160346263A1 - Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde - Google Patents

Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Download PDF

Info

Publication number
US20160346263A1
US20160346263A1 US15/236,283 US201615236283A US2016346263A1 US 20160346263 A1 US20160346263 A1 US 20160346263A1 US 201615236283 A US201615236283 A US 201615236283A US 2016346263 A1 US2016346263 A1 US 2016346263A1
Authority
US
United States
Prior art keywords
compound
crystalline
free base
radiation
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/236,283
Inventor
Zhe Li
Stephan D. PARENT
Travis HOUSTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53774359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160346263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Priority to US15/236,283 priority Critical patent/US20160346263A1/en
Publication of US20160346263A1 publication Critical patent/US20160346263A1/en
Assigned to AMRI SSCI, LLC reassignment AMRI SSCI, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOUSTON, TRAVIS, PARENT, STEPHAN D.
Assigned to GLOBAL BLOOD THERAPEUTICS, INC. reassignment GLOBAL BLOOD THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMRI SSCI, LLC
Assigned to GLOBAL BLOOD THERAPEUTICS, INC. reassignment GLOBAL BLOOD THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LI, ZHE
Priority to US15/801,152 priority patent/US10137118B2/en
Priority to US16/163,942 priority patent/US10722502B2/en
Priority to US16/923,498 priority patent/US11452720B2/en
Priority to US17/885,238 priority patent/US20220395492A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is a compound having the formula:
  • Sickle cell disease is a disorder of the red blood cells, found particularly among those of African and Mediterranean descent.
  • the basis for sickle cell disease is found in sickle hemoglobin (HbS), which contains a point mutation relative to the prevalent peptide sequence of hemoglobin (Hb).
  • Hemoglobin transports oxygen molecules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes.
  • Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing HbS to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels.
  • HbS abnormal Hb
  • 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde such as 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
  • a crystalline form of a therapeutic agent like 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, or a salt thereof, retains its polymorphic and chemical stability, solubility, and other physicochemical properties over time and among various manufactured batches of the agent. If the physicochemical properties vary with time and among batches, the administration of a therapeutically effective dose becomes problematic and may lead to toxic side effects or to ineffective therapy, particularly if a given polymorph decomposes prior to use, to a less active, inactive, or toxic compound. Therefore, it is important to choose a form of the crystalline agent that is stable, is manufactured reproducibly, and has physicochemical properties favorable for its use as a therapeutic agent.
  • This invention arises in part out the discovery that an HCl salt of Compound 1 disproportionates or loses HCl, and a disproportionation of the HCl salt of Compound 1 in water generates the free base and disproportionation was facile upon exposure to elevated humidity, with wet milling, and in direct contact with water (e.g. slurry).
  • the sulfate salt of Compound 1 also disproportionates from certain solvents such as dimethyl sulfoxide and methanol when precipitated with water.
  • the volatilization of HCl was evident within hours of exposure to drying conditions. For example, partial conversion to the free base was observed within 12 hours at 30° C. Accordingly, the free base of Compound 1 provides a stabler chemical entity compared to the corresponding HCl or sulfate and such other salt.
  • Free Base Forms I, II, and Material N Three anhydrous crystalline forms of the free base were identified, termed Free Base Forms I, II, and Material N. It has been discovered that nucleation of Free Base Form I generally occurs first from a slurry. Extending the slurry time can induce the transformation of Free Base Form I to Free Base Form II, a thermodynamically more stable phase relative to Form I. It has further been discovered that Free Base Material N can be stable relative to Forms I and II, at room temperature.
  • Free Base Material N was found to be enantiotropically related to Form II, and will transform reversibly at a specific transition temperature (estimated herein near 40-42° C.). Above the transition temperature, Free Base Form II appears to be the most stable form, relative to Form I and Material N. Thus, under operating temperatures below 40° C., e.g., at 30° C., the free base of Compound 1 exists primarily as Material N, which may have some residual Form II. Thus, at operating temperatures above 40° C., e.g., at 50° C., the free base of Compound 1 exists primarily as Form II, which may have some residual Material N. At 40° C. little appreciable conversion is seen between Material N and Form II.
  • the one or more crystalline free base forms of Compound 1 do not undergo polymorphic transformation under conditions suitable for manufacturing and storing the crystalline forms.
  • the crystalline free base of Compound 1 comprises crystalline Form I, which is characterized by an endothermic peak at (97 ⁇ 2) C as measured by differential scanning calorimetry.
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (97 ⁇ 2° C. as measured by differential scanning calorimetry.
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu K ⁇ radiation at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° ⁇ 0.2°2 ⁇ .
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu K ⁇ radiation) substantially similar to that of FIG. 3 .
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ⁇ 0.2°2 ⁇ ).
  • Form I is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • the crystalline Compound 1 free base comprises crystalline Form II, which is characterized by an endothermic peak at (97 ⁇ 2) C as measured by differential scanning calorimetry.
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (97 ⁇ 2° C. as measured by differential scanning calorimetry.
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu K ⁇ radiation at one or more of 13.37°, 14.37°, 19.95° or 23.92°2 ⁇ .
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu K ⁇ radiation) substantially similar to that of FIG. 5 .
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • Form II is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • the free base of crystalline Compound 1 comprises the crystalline Form II. In some preferred embodiments, the free base of crystalline Compound 1 comprises the crystalline Form II and less than 25 mole %, 10 mole % or 5 mole % of crystalline Form I, crystalline Material N or amorphous forms of Compound 1.
  • the crystalline Form II is prepared from a slurry comprising the free base of Compound 1 in heptane, from which the crystalline Form II is formed and filtered.
  • the crystalline Form II comprises residual (1-500 ppm) heptane.
  • the crystalline Form II is prepared from a slurry comprising the free base of Compound 1 in water, from which the crystalline Form II is formed and filtered.
  • the crystalline Form II can be prepared from a slurry comprising the free base of Compound 1 in heptane, which is suitable for good manufacturing practices (GMP) protocols. Further, in a most preferred embodiment, the crystalline Form II can be prepared from a slurry comprising the free base of Compound 1 in water or the HCl salt of Compound 1 in water, thus reducing or eliminating the need for solvent during recrystallization.
  • crystalline Form II of Compound 1 comprises less than 500 ppm, 100 ppm, less than 50 ppm or less than 10 ppm organic solvent.
  • Form II has less of a propensity than Material N to agglomerate upon size reduction, e.g., upon milling. As such, Form II has greater flowability than Material N. Certain illustrative and non-limiting advantages of Form II over Material N (i.e., Form N) are shown in the table below.
  • DATA/EXPERIMENT RESULTS/STATUS Identify suitable solvent Form N: for scale-up Limited number of suitable solvents compared to Form II MTBE identified (suitable for GMP; Class III solvent) Scale-up results look good Form II: More solvent options than Form N, including H 2 O Current solvent is heptane (suitable for GMP; Class III solvent) produced on 5 kg scale Formation time faster than N (could translate to 2-3 day saving in production time) Better recovery than N Size/Morphology of N Acicular morphology observed for form N; material and II composed of small and large particles Agglomerates are an issue for Form N relative to Form II (less agglomeration seen with energy-reduced method) PK Comparison of N and Oral administrations of GBT440 Forms N and II to rats II resulted in comparable exposure at 100 & 500 mg/kg
  • the crystalline Compound 1 free base comprises crystalline Material N, which is characterized by an endothermic peak at (95 ⁇ 2) C as measured by differential scanning calorimetry.
  • the terms “Material N”, “form N” and “polymorphic form N” are used interchangeably herein.
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (95 ⁇ 2° C. as measured by differential scanning calorimetry.
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu K ⁇ radiation at one or more of 11.65°, 11.85°, 12.08°, 16.70°, 19.65° or 23.48°2 ⁇ .
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu K ⁇ radiation) substantially similar to that of FIG. 7 .
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu K ⁇ radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2 ⁇ (each ⁇ 0.2°2 ⁇ ).
  • Material N is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • the free base of crystalline Compound 1 comprises the crystalline Material N and less than 25 mole %, 10 mole % or 5 mole % of crystalline Forms I or II or amorphous forms of Compound 1.
  • the crystalline Material N is prepared from a slurry comprising the free base of Compound 1 in methyl tertiary butyl ether (MTBE), from which the crystalline-Material N is formed and filtered.
  • MTBE methyl tertiary butyl ether
  • the crystalline Material N comprises residual (1-500 ppm) MTBE.
  • the crystalline Material N can be prepared from a slurry comprising the free base of Compound 1 in MTBE, which is suitable for good manufacturing practices (GMP) protocols.
  • GMP good manufacturing practices
  • the crystalline ansolvate forms are stable to contact with water, heptane, iso propyl ether (IPE), MTBE, and toluene, and such other solvents.
  • this invention provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline Compound 1 free base, comprising one or more of Form I, Form II or Material N.
  • this invention provides a method of preparing the solid crystalline free base of Compound 1 comprising, e.g., Form I, Form II and/or Material N.
  • a crystalline free base of Compound 1 comprising, e.g., Form I, Form II and/or Material N.
  • a crystalline free base of Compound 1 comprising, e.g., Form I, Form II and/or Material N.
  • This invention arises in part out of the discovery that ansolvate polymorphs of the free base of Compound 1 form solvate polymorphs with a variety of solvents, preferably other than certain hydrocarbon solvents, water and ethers.
  • Solvates of the crystalline free base of Compound 1 are also contemplated to be used e.g., as intermediates to regenerate the free base crystalline ansolvate of Compound 1.
  • Such methods can include, without limitation, subjecting the solvate to vacuum conditions; and/or generating a salt and disproportionating it in water to form the ansolvate; and/or slurrying or washing the solvate with a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • this invention provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more of the solvated crystal forms provided herein.
  • this invention provides a method of preparing the solvated crystal forms provided herein.
  • methods for increasing oxygen affinity of hemoglobin S in a subject comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the solvated crystal forms provided herein.
  • methods for treating oxygen deficiency associated with sickle cell anemia in a subject comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the solvated crystal forms provided herein.
  • FIG. 1 is a XRPD profile of the crystalline HCl salt before (top) and after (bottom) 5 minutes slurried in water.
  • FIG. 2 is a XRPD profile of the free base Form I (top), Form II (middle), and Material N (bottom).
  • FIG. 3 is a XRPD profile and contemplated indexing for free base Form I.
  • FIG. 4 is a thermal characterization for free base Form I.
  • FIG. 5 is a XRPD profile and contemplated indexing for free base Form II.
  • FIG. 6 is a thermal characterization for free base Form II.
  • FIG. 7 is a XRPD profile for free base Material N.
  • FIG. 8 is a thermal characterization for free base Material N.
  • FIG. 9 depicts an Energy-Temperature Diagram between the Free Base Forms I, II, and Material N.
  • the enthalpy (H) and free energy (G) isobars for each form are depicted as a function of temperature.
  • ⁇ H f is the heat of fusion
  • T is transition temperature
  • m melt temperature
  • superscripts I, II, and N refer to the polymorphs. *Under the test conditions, not enough information was available to graphically represent the free energy isobar of Form I below 6° C.
  • the isobar likely intersects G L at a temperature below m II , allowing the possibility that Form I may be enantiotropic with Form II (where T I-II occurs below 6° C.) and/or Material N (where either T I-N occurs below T I-II or T N-I occurs above T N-II , but not both). Free energy isobars can only intersect each other once.
  • FIG. 10 depicts 13 C Solid State NMR spectra for Free Base Forms I (bottom), II (middle), and Material N (top).
  • Form I contains one molecule per asymmetric unit.
  • Material N contains four molecules per asymmetric unit.
  • 13 C Solid State NMR spectra Forms II and N did not undergo a transition over 250 K to 340 K. Chemical shifts change slightly with temperature (not illustrated graphically).
  • FIG. 11 depicts 15 N Solid State NMR spectra for Free Base Forms I (bottom), II (middle), and Material N (top).
  • FIG. 12 depicts a differential scanning calorimetry (DSC) curve for Free Base Material N.
  • FIG. 13 depicts a DSC curve for Free Base Form II.
  • FIG. 14 depicts a DSC curve for Free Base Form I.
  • FIG. 15 depicts a XRPD profile of maturation experiments for the free base of Compound 1 at multiple temperatures.
  • FIG. 16 depicts a contemplated XRPD profile for solvated Material E.
  • FIG. 17 depicts a contemplated XRPD profile for solvated Material F.
  • FIG. 18 depicts a contemplated XRPD profile for solvated Material G.
  • FIG. 19 depicts a contemplated XRPD profile for solvated Material H.
  • FIG. 20 depicts a contemplated XRPD profile for solvated Material J.
  • FIG. 21 depicts a contemplated XRPD profile for solvated Material K.
  • FIG. 22 depicts a contemplated XRPD profile for solvated Material L.
  • FIG. 23 depicts a contemplated XRPD profile for solvated Material M.
  • FIG. 24 depicts a contemplated XRPD profile for solvated Material O.
  • FIG. 25 depicts an XRPD profile comparison of contemplated isostructural solvates of the free base of Compound 1. From top to bottom: Material E from acetone; Material F from ACN; Material G from DCM; Material H from dioxane; Material J from EtOH; Material K from IPA/water (also obtained from IPA); and Material L from THF, Material M from MEK.
  • this invention is directed, in part, to a stable free base of Compound 1 and, in particular, the free base Form I, Form II or Material N.
  • the free base Form I, Form II or Material N is defined.
  • administering refers to introducing an agent into a patient.
  • a therapeutic amount can be administered, which can be determined by the treating physician or the like.
  • An oral route of administration is preferred.
  • the related terms and phrases administering” and “administration of”, when used in connection with a compound or pharmaceutical composition (and grammatical equivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by self-administration by the patient, and/or to indirect administration, which may be the act of prescribing a drug.
  • a physician who instructs a patient to self-administer a drug and/or provides a patient with a prescription for a drug is administering the drug to the patient.
  • administration entails delivery to the patient of the drug.
  • the “crystalline ansolvate” of Compound 1 is a crystalline solid form of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, such as, e.g., crystalline Form I, Form II or Material N as disclosed herein.
  • Each of the Form I, Form II or Material N crystal lattices is substantially free of solvents of crystallization. However, any solvent present is not included in the crystal lattice and is randomly distributed outside the crystal lattice.
  • Form I, Form II or Material N crystals in bulk may contain, outside the crystal lattice, small amounts of one or more solvents, such as the solvents used in its synthesis or crystallization.
  • solvents such as the solvents used in its synthesis or crystallization.
  • substantially free of and “small amounts,” refers to the presence of solvents preferably less that 10,000 parts per million (ppm), or more preferably, less than 500 ppm.
  • the “crystalline solvate” of Compound 1 is a crystalline solid form of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, where the crystal lattices comprises one or more solvents of crystallization.
  • “Characterization” refers to obtaining data which may be used to identify a solid form of a compound, for example, to identify whether the solid form is amorphous or crystalline and whether it is unsolvated or solvated.
  • the process by which solid forms are characterized involves analyzing data collected on the polymorphic forms so as to allow one of ordinary skill in the art to distinguish one solid form from other solid forms containing the same material.
  • Chemical identity of solid forms can often be determined with solution-state techniques such as 13 C NMR or 1 H NMR. While these may help identify a material, and a solvent molecule for a solvate, such solution-state techniques themselves may not provide information about the solid state.
  • solid-state analytical techniques that can be used to provide information about solid-state structure and differentiate among polymorphic solid forms, such as single crystal X-ray diffraction, X-ray powder diffraction (XRPD), solid state nuclear magnetic resonance (SS-NMR), and infrared and Raman spectroscopy, and thermal techniques such as differential scanning calorimetry (DSC), Solid state 13 C-NMR, thermogravimetry (TG), melting point, and hot stage microscopy.
  • a solid form of a compound one may, for example, collect XRPD data on solid forms of the compound and compare the XRPD peaks of the forms. For example, when only three solid forms, e.g., Forms I and II and Material N, are compared and the Form I pattern shows a peak at an angle where no peaks appear in the Form II or Material N pattern, then that peak, for that compound, distinguishes Form I from Form II and Material N and further acts to characterize Form I.
  • the collection of peaks which distinguish e.g., Form I from the other known forms is a collection of peaks which may be used to characterize Form I.
  • An XRPD pattern is an x-y graph with diffraction angle (typically °2 ⁇ ) on the x-axis and intensity on the y-axis.
  • the peaks within this pattern may be used to characterize a crystalline solid form.
  • the data are often represented solely by the diffraction angle of the peaks rather than including the intensity of the peaks because peak intensity can be particularly sensitive to sample preparation (for example, particle size, moisture content, solvent content, and preferred orientation effects influence the sensitivity), so samples of the same material prepared under different conditions may yield slightly different patterns; this variability is usually greater than the variability in diffraction angles. Diffraction angle variability may also be sensitive to sample preparation.
  • compositions and methods include the recited elements, but not exclude others.
  • Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
  • Form II and Material N are enantiotropic at a transition temperature (of approximately 42° C.). Below this transition temperature, Material N of the free base of Compound 1 is the thermodynamically more stable form relative to Forms I and II. Above this transition temperature, Form II of the free base of Compound 1 is the thermodynamically more stable form relative to Form I and Material N.
  • Root temperature refers to (22 ⁇ 5)° C.
  • “Therapeutically effective amount” or “therapeutic amount” refers to an amount of a drug or an agent that when administered to a patient suffering from a condition, will have the intended therapeutic effect, e.g., alleviation, amelioration, palliation or elimination of one or more manifestations of the condition in the patient.
  • the therapeutically effective amount will vary depending upon the subject and the condition being treated, the weight and age of the subject, the severity of the condition, the particular composition or excipient chosen, the dosing regimen to be followed, timing of administration, the manner of administration and the like, all of which can be determined readily by one of ordinary skill in the art.
  • the full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
  • a therapeutically effective amount may be administered in one or more administrations.
  • a therapeutically effective amount of an agent in the context of treating disorders related to hemoglobin S, refers to an amount of the agent that alleviates, ameliorates, palliates, or eliminates one or more manifestations of the disorders related to hemoglobin S in the patient.
  • Treatment covers the treatment of a human patient, and includes: (a) reducing the risk of occurrence of the condition in a patient determined to be predisposed to the disease but not yet diagnosed as having the condition, (b) impeding the development of the condition, and/or (c) relieving the condition, i.e., causing regression of the condition and/or relieving one or more symptoms of the condition.
  • beneficial or desired clinical results include, but are not limited to, multilineage hematologic improvement, decrease in the number of required blood transfusions, decrease in infections, decreased bleeding, and the like.
  • Free Base Forms I, II, and Material N At least three anhydrous crystalline forms of the free base were identified, termed Free Base Forms I, II, and Material N. It was discovered that nucleation of Free Base Form I generally occurs first and that extending the slurry time induces the transformation of Free Base Form I to Free Base Form II, a more thermodynamically stable phase relative to Form I. It was further discovered that Free Base Material N appears to be most stable form, relative to Forms I and II, at room temperature.
  • Free Base Material N was found to be enantiotropically active relative to Form II, and will transform reversibly at a specific transition temperature (estimated herein near 42° C.). Above the transition temperature, Free Base Form II appears to be the most stable form, relative to Form I and Material N.
  • Form I contains one molecule per asymmetric unit
  • Form II contains two molecules per asymmetric unit
  • Form N contains four molecules per asymmetric unit. See the 15 N spectra in FIG. 11 .
  • this invention provides the free base crystalline ansolvate of Compound 1.
  • the free base crystalline ansolvate of Compound 1 may include one or more of Form I, Form II and/or Material N polymorphs.
  • the free base crystalline ansolvate of Compound 1 may include the Form II polymorph.
  • the free base crystalline ansolvate of Compound 1 may include Form II and/or Material N polymorphs.
  • the free base crystalline ansolvate of Compound 1 may include the Material N polymorph.
  • the free base crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1 free base.
  • the free base crystalline ansolvate of Compound 1 is substantially free of other ansolavte polymorphs of Compound 1 free base.
  • “Substantially free” of a component as used herein refers to contain up to about 5%, more preferably about 3%, and still more preferably about 1% of that component.
  • solvate includes a hydrate form as well.
  • the crystalline solvate is substantially free of an ansolvated polymorph of Compound 1.
  • Solvates were observed from the free base of Compound 1 in nine solvents including acetone (Material E), acetonitrile (Material F), dichloromethane (Material G), dioxane (Material H), ethanol (Material J), isopropyl alcohol or a mixture of water and isopropyl alcohol (Material K), tetrahydrofuran (Material L), methyl ethyl ketone “MEK” (Material M), ethyl acetate (Material O) and dimethyl sulfoxide “DMSO” (Material P).
  • solvents including acetone (Material E), acetonitrile (Material F), dichloromethane (Material G), dioxane (Material H), ethanol (Material J), isopropyl alcohol or a mixture of water and isopropyl alcohol (Material K), tetrahydrofuran (Material L
  • the majority of the solvates i.e., Materials E-H, J-M, O and P are contemplated to be isostructural.
  • the crystalline solvate includes one or more of Material E, Material F, Material G, Material H, Material J, Material K, Material L, Material M, Material O or Material P.
  • Material E can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.69, 11.73, 12.10, 15.26, 16.11, 17.45, 22.39, 22.55 and 23.70 ⁇ 0.20.
  • Material F can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.47, 8.81, 12.75, 13.17, 14.92, 15.63, 17.01 23.73, and 24.07 ⁇ 0.20.
  • Material G can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.47, 11.45, 12.62, 14.66, 15.69, 17.01, 18.47, 20.32, 22.61, 23.08, 23.43 and 23.70 ⁇ 0.20.
  • Material H can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.61, 11.67, 15.33, 16.28, 17.28, 22.58, 23.51 and 25.77 ⁇ 0.20.
  • Material J can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.52, 8.88, 12.79, 15.04, 15.61, 17.11, 22.81, 23.87, 24.17, 24.62 and 26.44 ⁇ 0.20.
  • Material K can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.52; 8.83, 11.35, 15.04, 15.74, 17.11, 23.46, 23.58, 24.08 and 25.99 ⁇ 0.20.
  • Material L can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 8.61, 8.78, 11.67, 14.94, 15.28, 16.14, 17.30, 22.75, 23.71 and 26.05 ⁇ 0.20; and Material M can be characterized by at least one X-ray powder diffraction peak (Cu K ⁇ radiation) selected from 7.74, 10.05, 12.82, 15.33, 16.80, 20.82, 21.14, 25.80 and 26.97 ⁇ 0.20.
  • Cu K ⁇ radiation X-ray powder diffraction peak
  • the solvates could be used e.g., as intermediates to regenerate the free base crystalline ansolvate of Compound 1 by several methods including subjecting the solvate to vacuum conditions; and/or regenerating the HCl salt and disproportionating HCl; and/or washing the solvate with a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • Certain contemplated peaks of the various solvates provided herein are tabulated below. Certain peaks, which are preferably non-overlapping, low-angle peaks, with strong intensity, were not identified. The peaks were determined to the extent that the state of preferred orientation in the samples were unknown.
  • this invention provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and crystalline free base ansolvate of Compound 1, preferably including one or more of the Form I, Form II and/or Material N polymorphs.
  • compositions suitable for oral delivery can be formulated for different routes of administration.
  • routes that may be used include intravenous, intraarterial, pulmonary, rectal, nasal, vaginal, lingual, intramuscular, intraperitoneal, intracutaneous, intracranial, subcutaneous and transdermal routes.
  • Suitable dosage forms for administering any of the compounds described herein include tablets, capsules, pills, powders, aerosols, suppositories, parenterals, and oral liquids, including suspensions, solutions and emulsions. Sustained release dosage forms may also be used, for example, in a transdermal patch form. All dosage forms may be prepared using methods that are standard in the art (see e.g., Remington's Pharmaceutical Sciences, 16 th ed., A. Oslo editor, Easton Pa. 1980).
  • compositions in accordance with the invention are prepared by conventional means using methods known in the art.
  • compositions disclosed herein may be used in conjunction with any of the vehicles and excipients commonly employed in pharmaceutical preparations, e.g., talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffin derivatives, glycols, etc. Coloring and flavoring agents may also be added to preparations, particularly to those for oral administration. Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethylsulfoxide, fatty alcohols, triglycerides, partial esters of glycerin and the like.
  • Solid pharmaceutical excipients include starch, cellulose, hydroxypropyl cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • the compositions provided herein comprises one or more of ⁇ -tocopherol, gum arabic, and/or hydroxypropyl cellulose.
  • this invention provides sustained release formulations such as drug depots or patches comprising an effective amount of a compound provided herein.
  • the patch further comprises gum Arabic or hydroxypropyl cellulose separately or in combination, in the presence of alpha-tocopherol.
  • the hydroxypropyl cellulose has an average MW of from 10,000 to 100,000. In a more preferred embodiment, the hydroxypropyl cellulose has an average MW of from 5,000 to 50,000.
  • co-administration can be in any manner in which the pharmacological effects of both are manifest in the patient at the same time.
  • co-administration does not require that a single pharmaceutical composition, the same dosage form, or even the same route of administration be used for administration of both the compound of this invention and the other agent or that the two agents be administered at precisely the same time.
  • co-administration will be accomplished most conveniently by the same dosage form and the same route of administration, at substantially the same time. Obviously, such administration most advantageously proceeds by delivering both active ingredients simultaneously in a novel pharmaceutical composition in accordance with the present invention.
  • the present invention provides a method of preparing the crystalline free base ansolvate of Compound 1.
  • a method of preparing the crystalline free base of Compound 1 comprising slurrying or contacting the HCl salt of the Compound 1 with water and allowing dissociation of HCl to produce the free base of Compound 1.
  • the crystalline free base ansolavte of Compound 1 prepared comprises one or more of Form I, Form II and Material N.
  • a method for treating sickle cell disease comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1.
  • the crystalline free base of Compound 1 is an ansolvate.
  • the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N.
  • a method is provided for treating cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer's disease, acute respiratory disease syndrome, and a wound, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1.
  • the crystalline free base of Compound 1 is an ansolvate.
  • the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N.
  • the solvent includes chlorinated solvents such as dichloromethane chloroform, et cetera.
  • the solvent includes ketone solvents such as alkanones and cycloalkanones.
  • Certain solvents include without limitation, methanol, ethanol, 2-propanol, 2-methyl-1-propanol, 1-butanol, acetonitrile, acetone, dichloromethane, dioxane, or tetrahydrofuran, or combinations thereof, optionally including water.
  • XRPD patterns are indexed by using proprietary SSCI software. Agreement between the allowed peak positions, marked with red bars within the figures, and the observed peaks indicates a consistent unit cell determination. Indexing and structure refinement are computational studies which are performed under the “Procedures for SSCI Non-cGMP Activities.” To confirm the tentative indexing solution, the molecular packing motifs within the crystallographic unit cells must be determined. No attempts at molecular packing were performed.
  • thermogram was performed using a TA Instruments Q2000 differential scanning calorimeter. Temperature calibration was performed using NIST-traceable indium metal. The sample was placed into an aluminum DSC pan, covered with a lid, and the weight was accurately recorded. A weighed aluminum pan configured as the sample pan was placed on the reference side of the cell. The data acquisition parameters and pan configuration for each thermogram are displayed in the image in the Data section of this report.
  • the method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., ⁇ 30-250-10 means “from ⁇ 30° C. to 250° C., at 10° C./min”.
  • TOC Tzero crimped pan
  • NC Lid not crimped
  • Dynamic vapor sorption (DVS) data were collected on a VTI SGA-100 Vapor Sorption Analyzer. NaCl and PVP were used as calibration standards. Samples were not dried prior to analysis. Adsorption and desorption data were collected over a range from 5 to 95% RH at 10% RH increments under a nitrogen purge. The equilibrium criterion used for analysis was less than 0.0100% weight change in 5 minutes with a maximum equilibration time of 3 hours. Data were not corrected for the initial moisture content of the samples.
  • Hot stage microscopy was performed using a Linkam hot stage (FTIR 600) mounted on a Leica DM LP microscope equipped with a SPOT InsightTM color digital camera. Temperature calibrations were performed using USP melting point standards. Samples were placed on a cover glass, and a second cover glass was placed on top of the sample. As the stage was heated, each sample was visually observed using a 20 ⁇ 0.40 N.A. long working distance objective with crossed polarizers and a first order red compensator. Images were captured using SPOT software (v. 4.5.9).
  • Samples were prepared for NMR spectroscopy as ⁇ 5-50 mg solutions in the appropriate deuterated solvent. The specific acquisition parameters are listed on the plot of the first full spectrum of each sample in the data section for samples run at SSCI.
  • XRPD patterns were collected with an Inel XRG-3000 diffractometer. An incident beam of Cu K ⁇ radiation was produced using a fine-focus tube and a parabolically graded multilayer mirror. Prior to the analysis, a silicon standard (NIST SRM 640d) was analyzed to verify the Si 111 peak position. A specimen of the sample was packed into a thin-walled glass capillary, and a beam-stop was used to minimize the background from air. Diffraction patterns were collected in transmission geometry using Windif v. 6.6 software and a curved position-sensitive Equinox detector with a 2 ⁇ range of 120°. The data-acquisition parameters for each pattern are displayed above the image in the Data section of this report.
  • XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation produced using an Optix long, fine-focus source.
  • An elliptically graded multilayer mirror was used to focus Cu K ⁇ X-rays through the specimen and onto the detector.
  • a silicon specimen NIST SRM 640d was analyzed to verify the Si 111 peak position.
  • a specimen of the sample was sandwiched between 3 ⁇ m thick films and analyzed in transmission geometry.
  • a beam-stop, short antiscatter extension, and an antiscatter knife edge were used to minimize the background generated by air.
  • Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence.
  • Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the specimen and Data Collector software v. 2.2b.
  • the data-acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) before the mirror and the incident-beam antiscatter slit (SS).
  • XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu K ⁇ radiation produced using a long, fine-focus source and a nickel filter.
  • the diffractometer was configured using the symmetric Bragg-Brentano geometry.
  • a silicon specimen NIST SRM 640d was analyzed to verify the observed position of the Si 111 peak is consistent with the NIST-certified position.
  • a specimen of the sample was prepared as a thin, circular layer centered on a silicon zero-background substrate.
  • Antiscatter slits (SS) were used to minimize the background generated by air.
  • Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence.
  • Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the sample and Data Collector software v. 2.2b.
  • the data acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) and the incident-beam SS.
  • Anti-Solvent Additions Compound 1/organic solvent solutions were contacted with solvents that Compound 1 was determined to be poorly soluble or insoluble in. These anti solvent additions were added to help lower the solubility of the solvent system and induce crystallization.
  • Solutions were prepared in the selected solvent or solvent/anti-solvent system. These solutions were chilled below room temperature within a refrigerator for varying lengths of time in an attempt to induce nucleation. The presence or absence of solids was noted. Upon observation of solids, in quantities sufficient for analysis, isolation of material was conduction. If insufficient quantities were present further cooling was performed in a freezer. Samples were either isolated for analysis wet or as dry powders.
  • Solutions were prepared in selected solvents and agitated between aliquot additions to assist in dissolution. Once a mixture reached complete dissolution, as judged by visual observation, the solution was allowed to evaporate at ambient temperature in an uncapped vial or at ambient under nitrogen. The solids that formed were isolated for evaluation.
  • Relative humidity jars saturated salt solutions used to generate desired relative humidity
  • the following relative humidity jars were utilized during evaluation: 75% RH (NaCl) and 60% (NaBr), to investigate the effects of humidity.
  • Temperatures utilized were ambient, 30, 40, 60, and 100-125° C.
  • Selected materials were stressed under reduced pressure for a set time period.
  • Initial stressing was conducted with the in-house vacuum system with absolute pressure readings ⁇ 500 mTorr, typically 30 to 50 mTorr (0.030 to 0.05 mm Hg). Additional vacuum stressing was conducted at 48 mmHg utilizing a portable lab vacuum and bleed to simulate conditions similar to those expected during process.
  • the disproportionation of the HCl salt in water was utilized to generate free base.
  • the nucleation of Free Base Form I occurs first. Extending the slurry time induces the transformation to a more thermodynamically stable phase relative to Form I, Free Base Form II.
  • HCl Form I The HCl salt (termed “HCl Form I”) was subjected to various stress conditions and monitored by XRPD to evaluate physical stability. As discussed, disproportionation occurred during the DVS experiment of the HCl salt, indicating instability upon exposure to elevated humidity. Disproportionation is further evident with wet milling or in direct contact with water (e.g. slurry) as shown by the presence of Free Base Forms I or II, identified by XRPD. The volatilization and loss of HCl upon heating and/or vacuum is shown by the presence of Free Base Form I, identified by XRPD, and also indicates instability at these conditions.
  • the HCl salt was shown to disproportionate immediately in water. This phenomenon was utilized to generate free base.
  • the nucleation of Free Base Form I occurs first. Extending the slurry time induces the transformation to a more thermodynamically stable phase relative to Form I, Free Base Form II.
  • the HCl salt of Compound 1 (134 g) was vigorously stirred in water (10 vol) until the material appeared as a finely dispersed white slurry. After filtration and drying, a white crystalline solid (116 g, 96% recovery, >99.9% purity by HPLC) was isolated.
  • XRPD patterns were indexed. Indexing is the process of determining the size and shape of the crystallographic unit cell given the peak positions in a diffraction pattern. The term gets its name from the assignment of Miller index labels to individual peaks. XRPD indexing serves several purposes. If all of the peaks in a pattern are indexed by a single unit cell, this is strong evidence that the sample contains a single crystalline phase. Given the indexing solution, the unit cell volume may be calculated directly and can be useful to determine their solvation states. Indexing is also a robust description of a crystalline form and provides a concise summary of all available peak positions for that phase at a particular thermodynamic state point.
  • Forms I, II, and Material N Three anhydrous materials were identified: Forms I, II, and Material N.
  • Material N appears to be most stable form, relative to Forms I and II, at room temperature.
  • Material N is enantiotropic relative to Form II, and will transform reversibly at a specific transition temperature (estimated near 42° C.). Above the transition temperature, Form II appears to be the most stable form, relative to Form I and Material N.
  • Free Base Form I is a metastable, anhydrous phase of the free base that is formed immediately from the disproportionation of the HCl salt in water.
  • a representative XRPD pattern of Form I was successfully indexed and the unit cell volume is consistent with anhydrous free base. Visual comparison of the XRPD pattern to the historical pattern of the free base provided indicates the material may be similar; however, the historical pattern appears to exhibit additional peaks from a potential mixture.
  • Thermograms (TG) data shows negligible weight loss, 0.2%, up to 100° C., consistent with an anhydrous form.
  • the DSC exhibits a single endotherm with an onset near 97° C. (similar to what is observed for Form II).
  • the endotherm is consistent with a melt by hot stage microscopy.
  • changes in particle size and birefringence were evident prior to the melt; a possible phase change occurred. Consequently, if a phase change occurred and an endotherm similar to that of Free Base Form II was observed, it can be inferred that the observed melt is truly not of Form I but of the resulting phase, most likely Form II.
  • the DVS isotherm indicates Form I is not hygroscopic. Negligible weight gain and loss, 0.2%, was observed through sorption/desorption.
  • XRPD the material recovered from the DVS experiment was predominately Free Base Form I with a few additional peaks. The additional peaks were termed Free Base Material D.
  • the nature of Material D is unknown; however, the appearance of another phase(s) indicates that Form I is not likely physically stable at elevated humidity conditions (at ambient temperature).
  • Free Base Form II is an anhydrous phase of the free base.
  • Form II is enantiotropically related to Material N, where it is the thermodynamically stable form above an estimated transition temperature of 42° C.
  • Form II can be generated in solvents that do not form known solvates; such as heptane, IPE, MTBE, or toluene; through short-term slurry conversions of Form I (where the crystallization kinetics delay the nucleation of the more stable form) or elevated temperature slurries (above 42° C.).
  • a representative XRPD pattern of Form II was successfully indexed and the unit cell volume is consistent with anhydrous free base of Compound 1.
  • Thermograms (TG) data show negligible weight loss, 0.1%, up to 100° C., consistent with an anhydrous form.
  • the DSC exhibits a single endotherm (80.1 J/g) with an onset near 97° C.
  • Form II remained unchanged after 7 days at ambient storage, through reanalysis by XRPD.
  • the form is known to be thermodynamically metastable, relative to Material N, at this condition; however, the kinetics of polymorph conversion may be slow at ambient conditions in the solid state.
  • Free Base Material N is an anhydrous phase of the free base.
  • Material N is enantiotropically related to Form II, where it is the thermodynamically stable form below an estimated transition temperature of 42° C. Given the opportunity, Material N can be generated through slurries in solvents that do not form known solvates; such as heptane, IPE, MTBE, or toluene; at temperatures below 42° C. The following is an example of a laboratory scale procedure used to generate Free Base Material N.
  • Thermograms (TG) data show negligible weight loss, 0.2%, up to 100° C., consistent with an anhydrous form.
  • the DSC exhibits a single endotherm (82.8 J/g) with an onset at 94° C.
  • Phase transitions of solids can be thermodynamically reversible or irreversible. Crystalline forms which transform reversibly at a specific transition temperature (T p ) are called enantiotropic polymorphs. If the crystalline forms are not interconvertable under these conditions, the system is monotropic (one thermodynamically stable form).
  • T p transition temperature
  • Several rules have been developed to predict the relative thermodynamic stability of polymorphs and whether the relationship between the polymorphs is enantiotropic or monotropic. The heat of fusion rule is applied within this study. The heat of fusion rule states that if the higher melting form has the lower heat of fusion then the two forms are enantiotropic, otherwise they are monotropic.
  • Material N appears to be most stable form, relative to Forms I and II, at room temperature. Based on the heats of fusion and melts determined by DSC, Material N is enantiotropic relative to Form II, and will transform reversibly at a specific transition temperature (T N-II ). Due to a possible phase change of Form I to Form II that occurred prior to the observed endotherm in the DSC, the relationship of Form I with either Material N or Form II cannot be conclusively determined through the heat of fusion rule. However, through various interconversion slurries, it was shown that Form I is the least thermodynamically stable form between 6° C. and T N-II . In addition, assuming that Form I spontaneously converted to Form II in the DSC at elevated temperatures (prior to the observed melt), it must follow that Form II is also more stable than Form I above T N-II .
  • the estimated transition temperature between two enantiotropically related forms can be calculated from their melt onsets and heats of fusion based on the equation shown below.
  • T p ⁇ ⁇ ⁇ H f , 2 - ⁇ ⁇ ⁇ H f , 1 + ( C p , liq - C p , 1 ) ⁇ ( T f , 1 - T f , 2 ) ⁇ ⁇ ⁇ H f , 2 T f , 2 - ⁇ ⁇ ⁇ H f , 1 T f , 1 + ( C p , liq - C p , 1 ) ⁇ ln ⁇ ( T f , 1 T f , 2 )
  • the Energy-Temperature Diagram of FIG. 17 is a semi-quantitative graphical solution of the Gibbs-Helmholtz equation, where the enthalpy (H) and free energy (G) isobars for each form are depicted as a function of temperature.
  • Interconversion experiments were performed to support the thermodynamic relationship between polymorphs illustrated by the Energy-Temperature Diagram above.
  • Interconversion or competitive slurry experiments are a solution-mediated process that provides a pathway for the less soluble (more stable) crystal to grow at the expense of the more soluble crystal form.
  • the resulting more stable polymorph from an interconversion experiment is contemplated to be independent of the solvent used because the more thermodynamically stable polymorph has a lower energy and therefore lower solubility.
  • the choice of solvent affects the kinetics of polymorph conversion and not the thermodynamic relationship between polymorphic forms.
  • Form I contains one molecule per asymmetric unit
  • Form II contains two molecules per asymmetric unit
  • Form N contains four molecules per asymmetric unit. See the 15 N spectra in FIG. 11 .
  • a mixture predominately composed of Free Base Form I (with Free Base Material D) were exposed to stability conditions to assess physical and chemical stability. Three conditions were used; open to 25° C./60% RH, open to 40° C./75% RH, and closed to 60° C. Physical stability was evaluated by XRPD. Chemical stability was determined through UPLC and 1 H NMR, when applicable. Materials were tested after 1, 7, and 14 days of exposure.
  • DSC was modulated at low underlying heating rate, followed by X-ray powder diffraction.
  • a low underlying heating rate was used of 0.02° C. mid′.
  • the temperature was 80° C. for form N and 90° C. for form II.
  • Exposure was essentially isothermal, covering a temperature range with sensitivity to detect changes in physical form.
  • the resultant materials were examined by X-ray powder diffraction. No changes in physical form were observed for either polymorphic form II or polymorphic form N (i.e., material N).
  • Forms II and N were exposed to 40° C./75% relative humidity (RH), 80° C., 80° C./80% RH for 9 days followed by X-ray powder diffraction. No changes in physical form were observed for either polymorphic form II or polymorphic form N.
  • thermodynamic barrier for inter-conversion between polymorphic form II and form N is high, and physical stability is good for both forms. Thermally induced inter-conversion between form II and form N is unlikely to occur.
  • Form N is thermodynamically more stable than form II at temperatures of 20° C. and lower.
  • An enantiotropic relationship between the two forms is likely to exhibit equivalence in thermodynamic stability at ca. 30-40° C.

Abstract

Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. Provisional Application No. 61/937,393 filed Feb. 7, 2014, and U.S. Provisional Application No. 61/937,404 filed Feb. 7, 2014, the contents of each of which is incorporated herein in its entirety by reference
    • BACKGROUND
  • 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is a compound having the formula:
  • Figure US20160346263A1-20161201-C00001
  • Sickle cell disease is a disorder of the red blood cells, found particularly among those of African and Mediterranean descent. The basis for sickle cell disease is found in sickle hemoglobin (HbS), which contains a point mutation relative to the prevalent peptide sequence of hemoglobin (Hb).
  • Hemoglobin (Hb) transports oxygen molecules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes. Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing HbS to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels. A need exists for therapeutics that can treat disorders that are mediated by Hb or by abnormal Hb such as HbS, such as 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
  • When used for treating humans, it is important that a crystalline form of a therapeutic agent, like 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, or a salt thereof, retains its polymorphic and chemical stability, solubility, and other physicochemical properties over time and among various manufactured batches of the agent. If the physicochemical properties vary with time and among batches, the administration of a therapeutically effective dose becomes problematic and may lead to toxic side effects or to ineffective therapy, particularly if a given polymorph decomposes prior to use, to a less active, inactive, or toxic compound. Therefore, it is important to choose a form of the crystalline agent that is stable, is manufactured reproducibly, and has physicochemical properties favorable for its use as a therapeutic agent.
  • However, the art remains unable to predict which crystalline form of an agent will have a combination of the desired properties and will be suitable for human administration, and how to make the agent in such a crystalline form.
    • SUMMARY Ansolvates
  • This invention arises in part out the discovery that an HCl salt of Compound 1 disproportionates or loses HCl, and a disproportionation of the HCl salt of Compound 1 in water generates the free base and disproportionation was facile upon exposure to elevated humidity, with wet milling, and in direct contact with water (e.g. slurry). The sulfate salt of Compound 1 also disproportionates from certain solvents such as dimethyl sulfoxide and methanol when precipitated with water. The volatilization of HCl was evident within hours of exposure to drying conditions. For example, partial conversion to the free base was observed within 12 hours at 30° C. Accordingly, the free base of Compound 1 provides a stabler chemical entity compared to the corresponding HCl or sulfate and such other salt.
  • It has now been discovered that 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1) i.e., the free base of Compound 1, can be obtained as one or more crystalline ansolvate forms, several of which are referred to here as crystalline Form I, Form II and Material N. In preferred embodiments, the free base of Compound 1 is a crystalline ansolvate, such as a crystalline anhydrous form. The free base of Compound 1, can be obtained from its corresponding salt form, such as the HCl salt of Compound 1.
  • Three anhydrous crystalline forms of the free base were identified, termed Free Base Forms I, II, and Material N. It has been discovered that nucleation of Free Base Form I generally occurs first from a slurry. Extending the slurry time can induce the transformation of Free Base Form I to Free Base Form II, a thermodynamically more stable phase relative to Form I. It has further been discovered that Free Base Material N can be stable relative to Forms I and II, at room temperature.
  • Free Base Material N was found to be enantiotropically related to Form II, and will transform reversibly at a specific transition temperature (estimated herein near 40-42° C.). Above the transition temperature, Free Base Form II appears to be the most stable form, relative to Form I and Material N. Thus, under operating temperatures below 40° C., e.g., at 30° C., the free base of Compound 1 exists primarily as Material N, which may have some residual Form II. Thus, at operating temperatures above 40° C., e.g., at 50° C., the free base of Compound 1 exists primarily as Form II, which may have some residual Material N. At 40° C. little appreciable conversion is seen between Material N and Form II. This is contemplated to be true for slurries of the free base in certain solvents and in the solid state. In one embodiment, the one or more crystalline free base forms of Compound 1 do not undergo polymorphic transformation under conditions suitable for manufacturing and storing the crystalline forms.
    • Form I
  • In one embodiment, the crystalline free base of Compound 1 comprises crystalline Form I, which is characterized by an endothermic peak at (97±2) C as measured by differential scanning calorimetry. In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (97±2° C. as measured by differential scanning calorimetry. In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu Kα radiation at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44°±0.2°2θ. In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 3.
  • In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ±0.2°2θ). In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ±0.2°2θ). In another embodiment, the crystalline Form I of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° (each ±0.2°2θ).
  • In another embodiment, Form I is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • Observed peaks for Form I, XRPD file 609973.
    °2θ d space (Å) Intensity (%)
     5.52 ± 0.20 16.021 ± 0.602  68
    12.82 ± 0.20 6.906 ± 0.109 74
    15.03 ± 0.20 5.897 ± 0.079 38
    15.74 ± 0.20 5.629 ± 0.072 46
    16.03 ± 0.20 5.530 ± 0.069 46
    16.63 ± 0.20 5.331 ± 0.064 61
    17.60 ± 0.20 5.040 ± 0.057 100
    18.74 ± 0.20 4.736 ± 0.051 24
    19.07 ± 0.20 4.654 ± 0.049 17
    19.35 ± 0.20 4.587 ± 0.047 23
    20.32 ± 0.20 4.370 ± 0.043 18
    21.64 ± 0.20 4.106 ± 0.038 23
    22.80 ± 0.20 3.901 ± 0.034 26
    23.28 ± 0.20 3.821 ± 0.033 34
    25.14 ± 0.20 3.543 ± 0.028 52
    25.82 ± 0.20 3.451 ± 0.026 81
    26.44 ± 0.20 3.371 ± 0.025 51
    27.91 ± 0.20 3.197 ± 0.023 17
    28.19 ± 0.20 3.165 ± 0.022 26
    • Form II
  • In another embodiment, the crystalline Compound 1 free base comprises crystalline Form II, which is characterized by an endothermic peak at (97±2) C as measured by differential scanning calorimetry. In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (97±2° C. as measured by differential scanning calorimetry. In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu Kα radiation at one or more of 13.37°, 14.37°, 19.95° or 23.92°2θ. In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5.
  • In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ). In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ). In another embodiment, the crystalline Form II of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
  • In another embodiment, Form II is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • Observed peaks for Form II, XRPD file 613881.
    °2θ d space (Å) Intensity (%)
     5.62 ± 0.20 15.735 ± 0.581  24
    12.85 ± 0.20 6.888 ± 0.108 22
    12.97 ± 0.20 6.826 ± 0.106 21
    13.37 ± 0.20 6.622 ± 0.100 100
    14.37 ± 0.20 6.162 ± 0.087 56
    15.31 ± 0.20 5.788 ± 0.076 21
    16.09 ± 0.20 5.507 ± 0.069 23
    16.45 ± 0.20 5.390 ± 0.066 69
    16.75 ± 0.20 5.294 ± 0.064 32
    16.96 ± 0.20 5.227 ± 0.062 53
    19.95 ± 0.20 4.450 ± 0.045 39
    20.22 ± 0.20 4.391 ± 0.043 20
    23.18 ± 0.20 3.837 ± 0.033 38
    23.92 ± 0.20 3.721 ± 0.031 41
    24.40 ± 0.20 3.648 ± 0.030 44
    24.73 ± 0.20 3.600 ± 0.029 22
    24.99 ± 0.20 3.564 ± 0.028 50
    25.12 ± 0.20 3.545 ± 0.028 28
    25.39 ± 0.20 3.509 ± 0.027 51
    25.70 ± 0.20 3.466 ± 0.027 21
    26.19 ± 0.20 3.403 ± 0.026 27
    26.72 ± 0.20 3.336 ± 0.025 30
    27.02 ± 0.20 3.300 ± 0.024 25
    27.34 ± 0.20 3.262 ± 0.024 23
    28.44 ± 0.20 3.138 ± 0.022 20
  • In some embodiments, the free base of crystalline Compound 1 comprises the crystalline Form II. In some preferred embodiments, the free base of crystalline Compound 1 comprises the crystalline Form II and less than 25 mole %, 10 mole % or 5 mole % of crystalline Form I, crystalline Material N or amorphous forms of Compound 1.
  • In a preferred embodiment, the crystalline Form II is prepared from a slurry comprising the free base of Compound 1 in heptane, from which the crystalline Form II is formed and filtered. Thus, in some embodiments, the crystalline Form II comprises residual (1-500 ppm) heptane. In another preferred embodiment, the crystalline Form II is prepared from a slurry comprising the free base of Compound 1 in water, from which the crystalline Form II is formed and filtered.
  • There are several advantages of crystalline Form II relative to crystalline Form I or Material N. For example, the crystalline Form II can be prepared from a slurry comprising the free base of Compound 1 in heptane, which is suitable for good manufacturing practices (GMP) protocols. Further, in a most preferred embodiment, the crystalline Form II can be prepared from a slurry comprising the free base of Compound 1 in water or the HCl salt of Compound 1 in water, thus reducing or eliminating the need for solvent during recrystallization. Thus, in some embodiments, crystalline Form II of Compound 1 comprises less than 500 ppm, 100 ppm, less than 50 ppm or less than 10 ppm organic solvent. Also, Form II has less of a propensity than Material N to agglomerate upon size reduction, e.g., upon milling. As such, Form II has greater flowability than Material N. Certain illustrative and non-limiting advantages of Form II over Material N (i.e., Form N) are shown in the table below.
  • DATA/EXPERIMENT RESULTS/STATUS
    Identify suitable solvent Form N:
    for scale-up   Limited number of suitable solvents compared to Form II
      MTBE identified (suitable for GMP; Class III solvent)
      Scale-up results look good
    Form II:
      More solvent options than Form N, including H2O
      Current solvent is heptane (suitable for GMP; Class III
      solvent)
      produced on 5 kg scale
      Formation time faster than N (could translate to 2-3 day
      saving in production time)
      Better recovery than N
    Size/Morphology of N   Acicular morphology observed for form N; material
    and II   composed of small and large particles
      Agglomerates are an issue for Form N relative to Form II
      (less agglomeration seen with energy-reduced method)
    PK Comparison of N and   Oral administrations of GBT440 Forms N and II to rats
    II   resulted in comparable exposure at 100 & 500 mg/kg
    • Material N
  • In another embodiment, the crystalline Compound 1 free base comprises crystalline Material N, which is characterized by an endothermic peak at (95±2) C as measured by differential scanning calorimetry. The terms “Material N”, “form N” and “polymorphic form N” are used interchangeably herein. In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by the substantial absence of thermal events at temperatures below the endothermic peak at (95±2° C. as measured by differential scanning calorimetry. In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction peak (Cu Kα radiation at one or more of 11.65°, 11.85°, 12.08°, 16.70°, 19.65° or 23.48°2θ. In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 7.
  • In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2θ (each ±0.2°2θ). In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2θ (each ±0.2°2θ). In another embodiment, the crystalline Material N of the free base of crystalline Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°2θ (each ±0.2°2θ).
  • In another embodiment, Material N is characterized by 1, 2, 3, 4, or more peaks as tabulated below.
  • Observed peaks for Material N, XRPD file 615765.
    °2θ d space (Å) Intensity (%)
     5.55 ± 0.20 15.924 ± 0.595  54
    11.65 ± 0.20 7.597 ± 0.132 31
    11.85 ± 0.20 7.468 ± 0.128 50
    12.08 ± 0.20 7.324 ± 0.123 31
    12.67 ± 0.20 6.987 ± 0.112 29
    13.12 ± 0.20 6.748 ± 0.104 83
    14.94 ± 0.20 5.929 ± 0.080 34
    15.19 ± 0.20 5.832 ± 0.077 56
    15.76 ± 0.20 5.623 ± 0.072 20
    16.70 ± 0.20 5.310 ± 0.064 100
    17.35 ± 0.20 5.112 ± 0.059 52
    19.65 ± 0.20 4.517 ± 0.046 60
    23.48 ± 0.20 3.789 ± 0.032 72
    23.68 ± 0.20 3.757 ± 0.032 29
    25.25 ± 0.20 3.527 ± 0.028 20
    25.47 ± 0.20 3.497 ± 0.027 20
    25.70 ± 0.20 3.466 ± 0.027 85
    26.04 ± 0.20 3.422 ± 0.026 35
    26.37 ± 0.20 3.380 ± 0.025 55
  • In some embodiments, the free base of crystalline Compound 1 comprises the crystalline Material N and less than 25 mole %, 10 mole % or 5 mole % of crystalline Forms I or II or amorphous forms of Compound 1.
  • In another embodiment, the crystalline Material N is prepared from a slurry comprising the free base of Compound 1 in methyl tertiary butyl ether (MTBE), from which the crystalline-Material N is formed and filtered. Thus, in some embodiments, the crystalline Material N comprises residual (1-500 ppm) MTBE.
  • There are several advantages of crystalline Material N relative to crystalline Forms I or II. For example, the crystalline Material N can be prepared from a slurry comprising the free base of Compound 1 in MTBE, which is suitable for good manufacturing practices (GMP) protocols.
  • In some embodiments, the crystalline ansolvate forms are stable to contact with water, heptane, iso propyl ether (IPE), MTBE, and toluene, and such other solvents.
  • In another of its composition embodiments, this invention provides for a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline Compound 1 free base, comprising one or more of Form I, Form II or Material N.
  • In one of its method embodiments, this invention provides a method of preparing the solid crystalline free base of Compound 1 comprising, e.g., Form I, Form II and/or Material N.
  • In yet another of its method embodiments, there are provided methods for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1, comprising, e.g., Form I, Form II and/or Material N.
  • In yet another of its method embodiments, there are provided methods for treating oxygen deficiency associated with sickle cell anemia in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1, comprising, e.g., Form I, Form II and/or Material N.
  • In all of such treatments, the effective amount of free base of Compound 1, comprising e.g., Form I, Form II and/or Material N to the treated patient is already disclosed in the art.
    • Solvates
  • This invention arises in part out of the discovery that ansolvate polymorphs of the free base of Compound 1 form solvate polymorphs with a variety of solvents, preferably other than certain hydrocarbon solvents, water and ethers.
  • Solvates of the crystalline free base of Compound 1 (e.g., from acetone, acetonitrile, dichloromethane, dioxane, ethanol, ethyl acetate, isopropyl alcohol, methyl ethyl ketone (MEK) and tetrahydrofuran) are also contemplated to be used e.g., as intermediates to regenerate the free base crystalline ansolvate of Compound 1. Such methods can include, without limitation, subjecting the solvate to vacuum conditions; and/or generating a salt and disproportionating it in water to form the ansolvate; and/or slurrying or washing the solvate with a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • In another of its composition embodiments, this invention provides for a pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more of the solvated crystal forms provided herein.
  • In one of its method embodiments, this invention provides a method of preparing the solvated crystal forms provided herein.
  • In yet another of its method embodiments, there are provided methods for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the solvated crystal forms provided herein.
  • In yet another of its method embodiments, there are provided methods for treating oxygen deficiency associated with sickle cell anemia in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the solvated crystal forms provided herein.
  • In all of such treatments, the effective amount of the free base of Compound 1, to the treated patient is already disclosed in the art.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a XRPD profile of the crystalline HCl salt before (top) and after (bottom) 5 minutes slurried in water.
  • FIG. 2 is a XRPD profile of the free base Form I (top), Form II (middle), and Material N (bottom).
  • FIG. 3 is a XRPD profile and contemplated indexing for free base Form I.
  • FIG. 4 is a thermal characterization for free base Form I.
  • FIG. 5 is a XRPD profile and contemplated indexing for free base Form II.
  • FIG. 6 is a thermal characterization for free base Form II.
  • FIG. 7 is a XRPD profile for free base Material N.
  • FIG. 8 is a thermal characterization for free base Material N.
  • FIG. 9 depicts an Energy-Temperature Diagram between the Free Base Forms I, II, and Material N. The enthalpy (H) and free energy (G) isobars for each form are depicted as a function of temperature. ΔHf is the heat of fusion; T is transition temperature; m is melt temperature; superscripts I, II, and N refer to the polymorphs. *Under the test conditions, not enough information was available to graphically represent the free energy isobar of Form I below 6° C. and above the estimated transition temperature TN-II; the isobar likely intersects GL at a temperature below mII, allowing the possibility that Form I may be enantiotropic with Form II (where TI-II occurs below 6° C.) and/or Material N (where either TI-N occurs below TI-II or TN-I occurs above TN-II, but not both). Free energy isobars can only intersect each other once.
  • FIG. 10 depicts 13C Solid State NMR spectra for Free Base Forms I (bottom), II (middle), and Material N (top). Form I contains one molecule per asymmetric unit. Material N contains four molecules per asymmetric unit. As observed by 13C Solid State NMR spectra, Forms II and N did not undergo a transition over 250 K to 340 K. Chemical shifts change slightly with temperature (not illustrated graphically).
  • FIG. 11 depicts 15N Solid State NMR spectra for Free Base Forms I (bottom), II (middle), and Material N (top).
  • FIG. 12 depicts a differential scanning calorimetry (DSC) curve for Free Base Material N.
  • FIG. 13 depicts a DSC curve for Free Base Form II.
  • FIG. 14 depicts a DSC curve for Free Base Form I.
  • FIG. 15 depicts a XRPD profile of maturation experiments for the free base of Compound 1 at multiple temperatures.
  • FIG. 16 depicts a contemplated XRPD profile for solvated Material E.
  • FIG. 17 depicts a contemplated XRPD profile for solvated Material F.
  • FIG. 18 depicts a contemplated XRPD profile for solvated Material G.
  • FIG. 19 depicts a contemplated XRPD profile for solvated Material H.
  • FIG. 20 depicts a contemplated XRPD profile for solvated Material J.
  • FIG. 21 depicts a contemplated XRPD profile for solvated Material K.
  • FIG. 22 depicts a contemplated XRPD profile for solvated Material L.
  • FIG. 23 depicts a contemplated XRPD profile for solvated Material M.
  • FIG. 24 depicts a contemplated XRPD profile for solvated Material O.
  • FIG. 25 depicts an XRPD profile comparison of contemplated isostructural solvates of the free base of Compound 1. From top to bottom: Material E from acetone; Material F from ACN; Material G from DCM; Material H from dioxane; Material J from EtOH; Material K from IPA/water (also obtained from IPA); and Material L from THF, Material M from MEK.
    •  DETAILED DESCRIPTION
  • As noted above, this invention is directed, in part, to a stable free base of Compound 1 and, in particular, the free base Form I, Form II or Material N. However, prior to discussing this invention in further detail, the following terms will be defined.
    • DEFINITIONS
  • As used herein, the following terms have the following meanings.
  • The singular forms “a,” “an,” and “the” and the like include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes both a single compound and a plurality of different compounds.
  • The term “about” when used before a numerical designation, e.g., temperature, time, amount, and concentration, including a range, indicates approximations which may vary by ±10%, ±5% or ±1%.
  • “Administration” refers to introducing an agent into a patient. A therapeutic amount can be administered, which can be determined by the treating physician or the like. An oral route of administration is preferred. The related terms and phrases administering” and “administration of”, when used in connection with a compound or pharmaceutical composition (and grammatical equivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by self-administration by the patient, and/or to indirect administration, which may be the act of prescribing a drug. For example, a physician who instructs a patient to self-administer a drug and/or provides a patient with a prescription for a drug is administering the drug to the patient. In any event, administration entails delivery to the patient of the drug.
  • The “crystalline ansolvate” of Compound 1 is a crystalline solid form of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, such as, e.g., crystalline Form I, Form II or Material N as disclosed herein. Each of the Form I, Form II or Material N crystal lattices is substantially free of solvents of crystallization. However, any solvent present is not included in the crystal lattice and is randomly distributed outside the crystal lattice. Therefore, Form I, Form II or Material N crystals in bulk may contain, outside the crystal lattice, small amounts of one or more solvents, such as the solvents used in its synthesis or crystallization. As used above, “substantially free of” and “small amounts,” refers to the presence of solvents preferably less that 10,000 parts per million (ppm), or more preferably, less than 500 ppm.
  • The “crystalline solvate” of Compound 1 is a crystalline solid form of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, where the crystal lattices comprises one or more solvents of crystallization.
  • “Characterization” refers to obtaining data which may be used to identify a solid form of a compound, for example, to identify whether the solid form is amorphous or crystalline and whether it is unsolvated or solvated. The process by which solid forms are characterized involves analyzing data collected on the polymorphic forms so as to allow one of ordinary skill in the art to distinguish one solid form from other solid forms containing the same material. Chemical identity of solid forms can often be determined with solution-state techniques such as 13C NMR or 1H NMR. While these may help identify a material, and a solvent molecule for a solvate, such solution-state techniques themselves may not provide information about the solid state. There are, however, solid-state analytical techniques that can be used to provide information about solid-state structure and differentiate among polymorphic solid forms, such as single crystal X-ray diffraction, X-ray powder diffraction (XRPD), solid state nuclear magnetic resonance (SS-NMR), and infrared and Raman spectroscopy, and thermal techniques such as differential scanning calorimetry (DSC), Solid state 13C-NMR, thermogravimetry (TG), melting point, and hot stage microscopy.
  • To “characterize” a solid form of a compound, one may, for example, collect XRPD data on solid forms of the compound and compare the XRPD peaks of the forms. For example, when only three solid forms, e.g., Forms I and II and Material N, are compared and the Form I pattern shows a peak at an angle where no peaks appear in the Form II or Material N pattern, then that peak, for that compound, distinguishes Form I from Form II and Material N and further acts to characterize Form I. The collection of peaks which distinguish e.g., Form I from the other known forms is a collection of peaks which may be used to characterize Form I. Those of ordinary skill in the art will recognize that there are often multiple ways, including multiple ways using the same analytical technique, to characterize solid forms. Additional peaks could also be used, but are not necessary, to characterize the form up to and including an entire diffraction pattern. Although all the peaks within an entire XRPD pattern may be used to characterize such a form, a subset of that data may, and typically is, used to characterize the form.
  • An XRPD pattern is an x-y graph with diffraction angle (typically °2θ) on the x-axis and intensity on the y-axis. The peaks within this pattern may be used to characterize a crystalline solid form. As with any data measurement, there is variability in XRPD data. The data are often represented solely by the diffraction angle of the peaks rather than including the intensity of the peaks because peak intensity can be particularly sensitive to sample preparation (for example, particle size, moisture content, solvent content, and preferred orientation effects influence the sensitivity), so samples of the same material prepared under different conditions may yield slightly different patterns; this variability is usually greater than the variability in diffraction angles. Diffraction angle variability may also be sensitive to sample preparation. Other sources of variability come from instrument parameters and processing of the raw X-ray data: different X-ray instruments operate using different parameters and these may lead to slightly different XRPD patterns from the same solid form, and similarly different software packages process X-ray data differently and this also leads to variability. These and other sources of variability are known to those of ordinary skill in the pharmaceutical arts. Due to such sources of variability, it is usual to assign a variability of ±0.2°2θ to diffraction angles in XRPD patterns.
  • “Comprising” or “comprises” is intended to mean that the compositions and methods include the recited elements, but not exclude others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
  • Form II and Material N are enantiotropic at a transition temperature (of approximately 42° C.). Below this transition temperature, Material N of the free base of Compound 1 is the thermodynamically more stable form relative to Forms I and II. Above this transition temperature, Form II of the free base of Compound 1 is the thermodynamically more stable form relative to Form I and Material N.
  • “Room temperature” refers to (22±5)° C.
  • “Therapeutically effective amount” or “therapeutic amount” refers to an amount of a drug or an agent that when administered to a patient suffering from a condition, will have the intended therapeutic effect, e.g., alleviation, amelioration, palliation or elimination of one or more manifestations of the condition in the patient. The therapeutically effective amount will vary depending upon the subject and the condition being treated, the weight and age of the subject, the severity of the condition, the particular composition or excipient chosen, the dosing regimen to be followed, timing of administration, the manner of administration and the like, all of which can be determined readily by one of ordinary skill in the art. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. For example, and without limitation, a therapeutically effective amount of an agent, in the context of treating disorders related to hemoglobin S, refers to an amount of the agent that alleviates, ameliorates, palliates, or eliminates one or more manifestations of the disorders related to hemoglobin S in the patient.
  • “Treatment”, “treating”, and “treat” are defined as acting upon a disease, disorder, or condition with an agent to reduce or ameliorate the harmful or any other undesired effects of the disease, disorder, or condition and/or its symptoms. Treatment, as used herein, covers the treatment of a human patient, and includes: (a) reducing the risk of occurrence of the condition in a patient determined to be predisposed to the disease but not yet diagnosed as having the condition, (b) impeding the development of the condition, and/or (c) relieving the condition, i.e., causing regression of the condition and/or relieving one or more symptoms of the condition. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, multilineage hematologic improvement, decrease in the number of required blood transfusions, decrease in infections, decreased bleeding, and the like.
    • Identifying Forms I, II and Material N
  • When the HCl salt of Compound 1 was subjected to various stress conditions, disproportionation of the HCl salt in water was observed to generate the free base. At least three anhydrous crystalline forms of the free base were identified, termed Free Base Forms I, II, and Material N. It was discovered that nucleation of Free Base Form I generally occurs first and that extending the slurry time induces the transformation of Free Base Form I to Free Base Form II, a more thermodynamically stable phase relative to Form I. It was further discovered that Free Base Material N appears to be most stable form, relative to Forms I and II, at room temperature. Free Base Material N was found to be enantiotropically active relative to Form II, and will transform reversibly at a specific transition temperature (estimated herein near 42° C.). Above the transition temperature, Free Base Form II appears to be the most stable form, relative to Form I and Material N.
  • Based in part on solid-state nuclear magnetic resonance data, all three forms are crystalline and are distinct polymorphic forms. See FIGS. 10 and 11. Form I contains one molecule per asymmetric unit, Form II contains two molecules per asymmetric unit and Form N contains four molecules per asymmetric unit. See the 15N spectra in FIG. 11.
    • Ansolvates of Forms I, II and Material N
  • In one embodiment, this invention provides the free base crystalline ansolvate of Compound 1. The free base crystalline ansolvate of Compound 1 may include one or more of Form I, Form II and/or Material N polymorphs. In some embodiments, the free base crystalline ansolvate of Compound 1 may include the Form II polymorph. Preferably, the free base crystalline ansolvate of Compound 1 may include Form II and/or Material N polymorphs. More preferably, the free base crystalline ansolvate of Compound 1 may include the Material N polymorph. Yet more preferably, the free base crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1 free base. Further yet more preferably, the free base crystalline ansolvate of Compound 1 is substantially free of other ansolavte polymorphs of Compound 1 free base. “Substantially free” of a component as used herein refers to contain up to about 5%, more preferably about 3%, and still more preferably about 1% of that component. As used herein, solvate includes a hydrate form as well.
    • Solvates of Compound 1
  • In one aspect, provided is a crystalline solvate of Compound 1:
  • Figure US20160346263A1-20161201-C00002
  • In some embodiments, the crystalline solvate is substantially free of an ansolvated polymorph of Compound 1.
  • Many of the solubility and screen experiments with the free base of Compound 1 resulted in precipitation of solids characterized as solvate formation with some solvents. Under the conditions, solvates were not observed from the free base of Compound 1 with four solvents, including heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene. Solvates were observed from the free base of Compound 1 in nine solvents including acetone (Material E), acetonitrile (Material F), dichloromethane (Material G), dioxane (Material H), ethanol (Material J), isopropyl alcohol or a mixture of water and isopropyl alcohol (Material K), tetrahydrofuran (Material L), methyl ethyl ketone “MEK” (Material M), ethyl acetate (Material O) and dimethyl sulfoxide “DMSO” (Material P). The majority of the solvates (i.e., Materials E-H, J-M, O and P are contemplated to be isostructural. In some embodiments, the crystalline solvate includes one or more of Material E, Material F, Material G, Material H, Material J, Material K, Material L, Material M, Material O or Material P.
  • Material E can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.69, 11.73, 12.10, 15.26, 16.11, 17.45, 22.39, 22.55 and 23.70±0.20. Material F can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.47, 8.81, 12.75, 13.17, 14.92, 15.63, 17.01 23.73, and 24.07±0.20. Material G can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.47, 11.45, 12.62, 14.66, 15.69, 17.01, 18.47, 20.32, 22.61, 23.08, 23.43 and 23.70±0.20. Material H can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.61, 11.67, 15.33, 16.28, 17.28, 22.58, 23.51 and 25.77±0.20. Material J can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.52, 8.88, 12.79, 15.04, 15.61, 17.11, 22.81, 23.87, 24.17, 24.62 and 26.44±0.20. Material K can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.52; 8.83, 11.35, 15.04, 15.74, 17.11, 23.46, 23.58, 24.08 and 25.99±0.20. Material L can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.61, 8.78, 11.67, 14.94, 15.28, 16.14, 17.30, 22.75, 23.71 and 26.05±0.20; and Material M can be characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 7.74, 10.05, 12.82, 15.33, 16.80, 20.82, 21.14, 25.80 and 26.97±0.20.
  • The solvates (such as, of acetone, acetonitrile, dichloromethane, dioxane, ethanol, ethyl acetate, isopropyl alcohol, MEK, tetrahydrofuran or DMSO) could be used e.g., as intermediates to regenerate the free base crystalline ansolvate of Compound 1 by several methods including subjecting the solvate to vacuum conditions; and/or regenerating the HCl salt and disproportionating HCl; and/or washing the solvate with a solvent less prone to solvate formation such as heptane, di-isopropyl ether (IPE), tert-methyl butyl ether (MTBE) and toluene.
  • TABLE 1
    Data Related to Solvates of the Free Base of Compound 1
    Estimated Volume
    Crystallization Volume Number of Formula per Formula Unit* Indexing
    Identifier Solvent (Å3/Cell) Units per Cell (Å3) Result
    Material E acetone 968 2 484 FIG 1
    Material F ACN 947 2 473 FIG 2
    Material G DCM 959 2 480 FIG 3
    Material H dioxane 977 2 488 FIG 4
    Material J EtOH 943 2 472 FIG 5
    Material K IPA 963 2 481 FIG 6
    Material L THF 972 2 486 FIG 7
    Material M MEK 3956 8 494 FIG 8
    Material O EtOAc — — — FIG 9
    Material DMSO — — — —
    P**
    *The value is obtained by dividing the volume of the cell, derived from the tentative indexing solution, by the number of formula units within the cell.
    **Material P was observed as a mixture with a “sulfate form I”.
  • Certain contemplated peaks of the various solvates provided herein are tabulated below. Certain peaks, which are preferably non-overlapping, low-angle peaks, with strong intensity, were not identified. The peaks were determined to the extent that the state of preferred orientation in the samples were unknown.
  • TABLE 2
    Observed peaks for Material E.
    °2θ d space (Å) Intensity (%)
     8.41 ± 0.20 10.517 ± 0.256  13
     8.69 ± 0.20 10.174 ± 0.239  100
    11.73 ± 0.20 7.543 ± 0.130 17
    12.10 ± 0.20 7.314 ± 0.122 20
    13.00 ± 0.20 6.809 ± 0.106 15
    14.02 ± 0.20 6.316 ± 0.091 5
    14.77 ± 0.20 5.996 ± 0.082 16
    15.26 ± 0.20 5.807 ± 0.077 34
    15.81 ± 0.20 5.605 ± 0.071 7
    16.11 ± 0.20 5.501 ± 0.069 20
    16.48 ± 0.20 5.379 ± 0.066 11
    16.65 ± 0.20 5.326 ± 0.064 11
    16.88 ± 0.20 5.253 ± 0.063 3
    17.26 ± 0.20 5.136 ± 0.060 9
    17.45 ± 0.20 5.083 ± 0.058 32
    20.02 ± 0.20 4.435 ± 0.044 2
    20.92 ± 0.20 4.246 ± 0.041 13
    21.91 ± 0.20 4.057 ± 0.037 20
    22.39 ± 0.20 3.970 ± 0.035 49
    22.55 ± 0.20 3.944 ± 0.035 37
    22.81 ± 0.20 3.898 ± 0.034 16
    23.36 ± 0.20 3.807 ± 0.032 12
    23.70 ± 0.20 3.755 ± 0.032 61
    24.37 ± 0.20 3.653 ± 0.030 12
    24.85 ± 0.20 3.583 ± 0.029 5
    25.42 ± 0.20 3.504 ± 0.027 2
    25.89 ± 0.20 3.442 ± 0.026 8
    26.19 ± 0.20 3.403 ± 0.026 40
    26.97 ± 0.20 3.306 ± 0.024 3
    27.61 ± 0.20 3.231 ± 0.023 16
    28.24 ± 0.20 3.160 ± 0.022 2
    28.48 ± 0.20 3.134 ± 0.022 5
    28.69 ± 0.20 3.111 ± 0.021 7
    29.83 ± 0.20 2.995 ± 0.020 4
  • TABLE 3
    Observed peaks for Material F.
    °2θ d space (Å) Intensity (%)
     8.47 ± 0.20 10.434 ± 0.252  100
     8.81 ± 0.20 10.039 ± 0.233  49
    11.42 ± 0.20 7.752 ± 0.138 15
    12.75 ± 0.20 6.942 ± 0.110 27
    13.17 ± 0.20 6.723 ± 0.103 21
    13.87 ± 0.20 6.384 ± 0.093 7
    14.61 ± 0.20 6.064 ± 0.084 13
    14.92 ± 0.20 5.936 ± 0.080 43
    15.51 ± 0.20 5.713 ± 0.074 24
    15.63 ± 0.20 5.671 ± 0.073 43
    15.96 ± 0.20 5.553 ± 0.070 15
    17.01 ± 0.20 5.212 ± 0.062 31
    17.26 ± 0.20 5.136 ± 0.060 4
    17.70 ± 0.20 5.011 ± 0.057 9
    18.17 ± 0.20 4.883 ± 0.054 4
    18.79 ± 0.20 4.724 ± 0.050 10
    19.35 ± 0.20 4.587 ± 0.047 4
    19.49 ± 0.20 4.555 ± 0.047 3
    20.02 ± 0.20 4.435 ± 0.044 4
    20.29 ± 0.20 4.377 ± 0.043 9
    21.06 ± 0.20 4.219 ± 0.040 11
    21.33 ± 0.20 4.167 ± 0.039 4
    22.71 ± 0.20 3.915 ± 0.034 27
    23.11 ± 0.20 3.848 ± 0.033 15
    23.73 ± 0.20 3.749 ± 0.031 42
    24.07 ± 0.20 3.698 ± 0.031 59
    24.65 ± 0.20 3.612 ± 0.029 87
    24.95 ± 0.20 3.569 ± 0.028 6
    25.20 ± 0.20 3.534 ± 0.028 5
    25.69 ± 0.20 3.468 ± 0.027 15
    26.52 ± 0.20 3.361 ± 0.025 61
    26.79 ± 0.20 3.328 ± 0.025 10
    27.02 ± 0.20 3.300 ± 0.024 9
  • TABLE 4
    Observed peaks for Material G.
    °2θ d space (Å) Intensity (%)
     8.47 ± 0.20 10.434 ± 0.252  45
     8.76 ± 0.20 10.096 ± 0.235  12
    11.45 ± 0.20 7.729 ± 0.137 76
    12.62 ± 0.20 7.015 ± 0.113 36
    13.09 ± 0.20 6.765 ± 0.105 10
    13.87 ± 0.20 6.384 ± 0.093 5
    14.66 ± 0.20 6.044 ± 0.083 39
    14.92 ± 0.20 5.936 ± 0.080 26
    15.33 ± 0.20 5.782 ± 0.076 7
    15.69 ± 0.20 5.647 ± 0.072 88
    16.01 ± 0.20 5.536 ± 0.070 8
    16.76 ± 0.20 5.289 ± 0.063 15
    17.01 ± 0.20 5.212 ± 0.062 29
    17.50 ± 0.20 5.068 ± 0.058 5
    17.60 ± 0.20 5.040 ± 0.057 4
    18.13 ± 0.20 4.892 ± 0.054 5
    18.47 ± 0.20 4.804 ± 0.052 21
    19.55 ± 0.20 4.540 ± 0.046 4
    20.01 ± 0.20 4.439 ± 0.044 5
    20.32 ± 0.20 4.370 ± 0.043 20
    21.11 ± 0.20 4.209 ± 0.040 15
    22.61 ± 0.20 3.932 ± 0.035 42
    22.88 ± 0.20 3.887 ± 0.034 9
    23.08 ± 0.20 3.854 ± 0.033 28
    23.43 ± 0.20 3.797 ± 0.032 56
    23.70 ± 0.20 3.755 ± 0.032 48
    24.12 ± 0.20 3.690 ± 0.030 13
    24.42 ± 0.20 3.646 ± 0.030 100
    25.05 ± 0.20 3.555 ± 0.028 7
    25.40 ± 0.20 3.506 ± 0.027 26
    26.36 ± 0.20 3.382 ± 0.025 50
    26.57 ± 0.20 3.355 ± 0.025 7
    26.82 ± 0.20 3.324 ± 0.025 27
    27.07 ± 0.20 3.294 ± 0.024 10
  • TABLE 5
    Observed peaks for Material H.
    °2θ d space (Å) Intensity (%)
     8.61 ± 0.20 10.273 ± 0.244  48
     8.81 ± 0.20 10.039 ± 0.233  20
    11.67 ± 0.20 7.586 ± 0.132 32
    12.10 ± 0.20 7.314 ± 0.122 11
    12.79 ± 0.20 6.924 ± 0.110 9
    14.56 ± 0.20 6.085 ± 0.084 4
    14.87 ± 0.20 5.956 ± 0.081 22
    15.33 ± 0.20 5.782 ± 0.076 42
    15.76 ± 0.20 5.623 ± 0.072 18
    16.28 ± 0.20 5.445 ± 0.067 51
    16.73 ± 0.20 5.299 ± 0.064 9
    17.28 ± 0.20 5.132 ± 0.060 61
    17.68 ± 0.20 5.016 ± 0.057 3
    20.47 ± 0.20 4.338 ± 0.042 12
    21.38 ± 0.20 4.157 ± 0.039 7
    21.83 ± 0.20 4.072 ± 0.037 4
    22.23 ± 0.20 3.999 ± 0.036 9
    22.58 ± 0.20 3.938 ± 0.035 100
    22.95 ± 0.20 3.876 ± 0.034 6
    23.11 ± 0.20 3.848 ± 0.033 14
    23.51 ± 0.20 3.783 ± 0.032 88
    24.37 ± 0.20 3.653 ± 0.030 13
    24.65 ± 0.20 3.612 ± 0.029 10
    25.77 ± 0.20 3.457 ± 0.027 41
    26.67 ± 0.20 3.342 ± 0.025 7
    26.97 ± 0.20 3.306 ± 0.024 5
    27.66 ± 0.20 3.225 ± 0.023 3
    28.11 ± 0.20 3.174 ± 0.022 4
    28.61 ± 0.20 3.120 ± 0.022 6
    28.96 ± 0.20 3.083 ± 0.021 4
    29.23 ± 0.20 3.055 ± 0.021 3
    29.63 ± 0.20 3.015 ± 0.020 3
  • TABLE 6
    Observed peaks for Material J.
    °2θ d space (Å) Intensity (%)
     8.52 ± 0.20 10.373 ± 0.249  100
     8.88 ± 0.20 9.964 ± 0.229 39
    11.33 ± 0.20 7.809 ± 0.140 22
    12.79 ± 0.20 6.924 ± 0.110 25
    13.12 ± 0.20 6.748 ± 0.104 24
    13.94 ± 0.20 6.354 ± 0.092 4
    14.47 ± 0.20 6.120 ± 0.085 14
    15.04 ± 0.20 5.890 ± 0.079 42
    15.61 ± 0.20 5.677 ± 0.073 56
    15.84 ± 0.20 5.594 ± 0.071 16
    17.11 ± 0.20 5.181 ± 0.061 33
    17.40 ± 0.20 5.097 ± 0.059 4
    17.82 ± 0.20 4.979 ± 0.056 8
    18.12 ± 0.20 4.897 ± 0.054 3
    18.90 ± 0.20 4.695 ± 0.050 11
    19.39 ± 0.20 4.579 ± 0.047 5
    19.62 ± 0.20 4.525 ± 0.046 4
    20.16 ± 0.20 4.406 ± 0.044 8
    20.96 ± 0.20 4.239 ± 0.040 12
    22.81 ± 0.20 3.898 ± 0.034 27
    23.15 ± 0.20 3.843 ± 0.033 9
    23.28 ± 0.20 3.821 ± 0.033 7
    23.87 ± 0.20 3.729 ± 0.031 34
    24.17 ± 0.20 3.683 ± 0.030 52
    24.62 ± 0.20 3.616 ± 0.029 95
    25.20 ± 0.20 3.534 ± 0.028 5
    25.77 ± 0.20 3.457 ± 0.027 13
    26.44 ± 0.20 3.371 ± 0.025 70
    26.71 ± 0.20 3.338 ± 0.025 10
    27.21 ± 0.20 3.278 ± 0.024 7
  • TABLE 7
    Observed peaks for GBT000440, Material K.
    °2θ d space (Å) Intensity (%)
     8.52 ± 0.20 10.373 ± 0.249  75
     8.83 ± 0.20 10.020 ± 0.232  33
    11.35 ± 0.20 7.797 ± 0.139 29
    12.52 ± 0.20 7.071 ± 0.114 21
    12.90 ± 0.20 6.861 ± 0.108 24
    13.92 ± 0.20 6.361 ± 0.092 4
    14.49 ± 0.20 6.113 ± 0.085 18
    15.04 ± 0.20 5.890 ± 0.079 41
    15.34 ± 0.20 5.775 ± 0.076 17
    15.74 ± 0.20 5.629 ± 0.072 57
    15.93 ± 0.20 5.564 ± 0.070 13
    16.61 ± 0.20 5.336 ± 0.065 7
    17.11 ± 0.20 5.181 ± 0.061 33
    17.70 ± 0.20 5.011 ± 0.057 7
    18.00 ± 0.20 4.928 ± 0.055 4
    18.38 ± 0.20 4.826 ± 0.053 13
    19.04 ± 0.20 4.662 ± 0.049 4
    19.74 ± 0.20 4.498 ± 0.046 5
    20.21 ± 0.20 4.395 ± 0.043 11
    20.99 ± 0.20 4.232 ± 0.040 12
    22.70 ± 0.20 3.918 ± 0.034 22
    22.90 ± 0.20 3.884 ± 0.034 17
    23.46 ± 0.20 3.791 ± 0.032 45
    23.58 ± 0.20 3.773 ± 0.032 70
    24.08 ± 0.20 3.695 ± 0.030 100
    24.75 ± 0.20 3.597 ± 0.029 6
    25.19 ± 0.20 3.536 ± 0.028 21
    25.99 ± 0.20 3.429 ± 0.026 71
    26.71 ± 0.20 3.338 ± 0.025 11
    27.36 ± 0.20 3.260 ± 0.024 9
    28.11 ± 0.20 3.174 ± 0.022 4
    28.69 ± 0.20 3.111 ± 0.021 9
  • TABLE 8
    Observed peaks for Material L.
    °2θ d space (Å) Intensity (%)
     8.61 ± 0.20 10.273 ± 0.244  79
     8.78 ± 0.20 10.077 ± 0.235  38
    11.67 ± 0.20 7.586 ± 0.132 35
    12.17 ± 0.20 7.274 ± 0.121 19
    12.94 ± 0.20 6.844 ± 0.107 14
    14.07 ± 0.20 6.293 ± 0.090 3
    14.62 ± 0.20 6.057 ± 0.084 5
    14.94 ± 0.20 5.929 ± 0.080 25
    15.28 ± 0.20 5.800 ± 0.076 50
    15.93 ± 0.20 5.564 ± 0.070 18
    16.14 ± 0.20 5.490 ± 0.068 49
    16.33 ± 0.20 5.429 ± 0.067 9
    16.70 ± 0.20 5.310 ± 0.064 9
    16.85 ± 0.20 5.263 ± 0.063 6
    17.30 ± 0.20 5.127 ± 0.060 52
    17.63 ± 0.20 5.030 ± 0.057 6
    18.37 ± 0.20 4.830 ± 0.053 3
    20.14 ± 0.20 4.409 ± 0.044 5
    20.59 ± 0.20 4.314 ± 0.042 14
    21.53 ± 0.20 4.128 ± 0.038 11
    22.01 ± 0.20 4.038 ± 0.037 3
    22.44 ± 0.20 3.961 ± 0.035 27
    22.75 ± 0.20 3.910 ± 0.034 72
    23.10 ± 0.20 3.851 ± 0.033 20
    23.31 ± 0.20 3.816 ± 0.033 19
    23.48 ± 0.20 3.789 ± 0.032 12
    23.71 ± 0.20 3.752 ± 0.031 100
    24.48 ± 0.20 3.636 ± 0.029 20
    24.70 ± 0.20 3.604 ± 0.029 4
    24.93 ± 0.20 3.571 ± 0.028 3
    25.59 ± 0.20 3.482 ± 0.027 5
    25.72 ± 0.20 3.464 ± 0.027 5
    26.05 ± 0.20 3.420 ± 0.026 62
    26.59 ± 0.20 3.352 ± 0.025 6
    27.14 ± 0.20 3.286 ± 0.024 8
    27.83 ± 0.20 3.206 ± 0.023 8
    28.38 ± 0.20 3.145 ± 0.022 3
    28.78 ± 0.20 3.102 ± 0.021 8
    29.05 ± 0.20 3.074 ± 0.021 4
    29.36 ± 0.20 3.042 ± 0.020 3
  • TABLE 9
    Observed peaks for Material M.
    °2θ d space (Å) Intensity (%)
     7.74 ± 0.20 11.424 ± 0.303  100
     8.34 ± 0.20 10.601 ± 0.260  4
    10.05 ± 0.20 8.806 ± 0.178 17
    12.82 ± 0.20 6.906 ± 0.109 46
    13.05 ± 0.20 6.783 ± 0.105 4
    14.17 ± 0.20 6.249 ± 0.089 2
    14.54 ± 0.20 6.092 ± 0.085 6
    14.99 ± 0.20 5.910 ± 0.079 16
    15.33 ± 0.20 5.782 ± 0.076 47
    15.53 ± 0.20 5.707 ± 0.074 21
    16.80 ± 0.20 5.278 ± 0.063 27
    18.33 ± 0.20 4.839 ± 0.053 3
    19.17 ± 0.20 4.630 ± 0.048 22
    20.19 ± 0.20 4.399 ± 0.044 23
    20.82 ± 0.20 4.266 ± 0.041 32
    21.14 ± 0.20 4.202 ± 0.040 27
    21.29 ± 0.20 4.173 ± 0.039 14
    22.01 ± 0.20 4.038 ± 0.037 13
    22.28 ± 0.20 3.991 ± 0.036 23
    22.93 ± 0.20 3.879 ± 0.034 6
    23.35 ± 0.20 3.810 ± 0.032 11
    24.00 ± 0.20 3.708 ± 0.031 14
    24.25 ± 0.20 3.670 ± 0.030 3
    24.88 ± 0.20 3.578 ± 0.029 11
    25.54 ± 0.20 3.488 ± 0.027 9
    25.80 ± 0.20 3.453 ± 0.027 94
    26.97 ± 0.20 3.306 ± 0.024 27
    27.63 ± 0.20 3.229 ± 0.023 2
    28.41 ± 0.20 3.142 ± 0.022 7
    28.54 ± 0.20 3.127 ± 0.022 8
    29.03 ± 0.20 3.076 ± 0.021 3
    29.30 ± 0.20 3.049 ± 0.020 7
    29.63 ± 0.20 3.015 ± 0.020 15
    • Pharmaceutical Compositions
  • In another of its composition embodiments, this invention provides for a pharmaceutical composition comprising a pharmaceutically acceptable excipient and crystalline free base ansolvate of Compound 1, preferably including one or more of the Form I, Form II and/or Material N polymorphs.
  • Such compositions can be formulated for different routes of administration. Although compositions suitable for oral delivery will probably be used most frequently, other routes that may be used include intravenous, intraarterial, pulmonary, rectal, nasal, vaginal, lingual, intramuscular, intraperitoneal, intracutaneous, intracranial, subcutaneous and transdermal routes. Suitable dosage forms for administering any of the compounds described herein include tablets, capsules, pills, powders, aerosols, suppositories, parenterals, and oral liquids, including suspensions, solutions and emulsions. Sustained release dosage forms may also be used, for example, in a transdermal patch form. All dosage forms may be prepared using methods that are standard in the art (see e.g., Remington's Pharmaceutical Sciences, 16th ed., A. Oslo editor, Easton Pa. 1980).
  • Pharmaceutically acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of this invention. Such excipients may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. Pharmaceutical compositions in accordance with the invention are prepared by conventional means using methods known in the art.
  • The compositions disclosed herein may be used in conjunction with any of the vehicles and excipients commonly employed in pharmaceutical preparations, e.g., talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffin derivatives, glycols, etc. Coloring and flavoring agents may also be added to preparations, particularly to those for oral administration. Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethylsulfoxide, fatty alcohols, triglycerides, partial esters of glycerin and the like.
  • Solid pharmaceutical excipients include starch, cellulose, hydroxypropyl cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. In certain embodiments, the compositions provided herein comprises one or more of α-tocopherol, gum arabic, and/or hydroxypropyl cellulose.
  • In one embodiment, this invention provides sustained release formulations such as drug depots or patches comprising an effective amount of a compound provided herein. In another embodiment, the patch further comprises gum Arabic or hydroxypropyl cellulose separately or in combination, in the presence of alpha-tocopherol. Preferably, the hydroxypropyl cellulose has an average MW of from 10,000 to 100,000. In a more preferred embodiment, the hydroxypropyl cellulose has an average MW of from 5,000 to 50,000.
  • Compounds and pharmaceutical compositions of this invention maybe used alone or in combination with other compounds. When administered with another agent, the co-administration can be in any manner in which the pharmacological effects of both are manifest in the patient at the same time. Thus, co-administration does not require that a single pharmaceutical composition, the same dosage form, or even the same route of administration be used for administration of both the compound of this invention and the other agent or that the two agents be administered at precisely the same time. However, co-administration will be accomplished most conveniently by the same dosage form and the same route of administration, at substantially the same time. Obviously, such administration most advantageously proceeds by delivering both active ingredients simultaneously in a novel pharmaceutical composition in accordance with the present invention.
    • Preparative and Treatment Methods Ansolvate
  • In another aspect, the present invention provides a method of preparing the crystalline free base ansolvate of Compound 1. In one embodiment, provided herein is a method of preparing the crystalline free base of Compound 1 comprising slurrying or contacting the HCl salt of the Compound 1 with water and allowing dissociation of HCl to produce the free base of Compound 1. In one embodiment, the crystalline free base ansolavte of Compound 1 prepared comprises one or more of Form I, Form II and Material N.
  • In yet another of its method embodiments, there are provided methods for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1. In some embodiments, the crystalline free base of Compound 1 is an ansolvate. In one embodiment, the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N.
  • In yet another of its method embodiments, there are provided methods for treating oxygen deficiency associated with sickle cell anemia in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1. In some embodiments, the crystalline free base of Compound 1 is an ansolvate. In one embodiment, the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N.
  • In further aspects of the invention, a method is provided for treating sickle cell disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1. In some embodiments, the crystalline free base of Compound 1 is an ansolvate. In one embodiment, the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N. In still further aspects of the invention, a method is provided for treating cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer's disease, acute respiratory disease syndrome, and a wound, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline free base of Compound 1. In some embodiments, the crystalline free base of Compound 1 is an ansolvate. In one embodiment, the crystalline free base of Compound 1 comprises one or more of Form I, Form II and Material N.
  • In such treatments, the dosing of the crystalline free base of Compound 1 to the treated patient is already disclosed in the art.
    • Solvates
  • In another aspect, the present invention provides a method of preparing the crystalline free base solvates of Compound 1. In some embodiments, a free base ansolvate, as described herein (e.g, as obtained by slurrying an HCl salt of Compound 1 in water) of Compound 1 is contacted with a solvent as provided herein, including a mixture of solvents, to prepare the solvate. the solvent or the mixture of solvents. Thus, a solvent can be a single solvent or substantially a single solvent or a mixture of solvents. When a mixture of solvents is used, a solvate can be produced having one or more of the individual constituent solvents of the solvent mixture. In some embodiments, the solvent includes alcoholic solvents such as mono di or higher alcohols or alkanols. In some embodiments, the solvent includes chlorinated solvents such as dichloromethane chloroform, et cetera. In some embodiments, the solvent includes ketone solvents such as alkanones and cycloalkanones. Certain solvents include without limitation, methanol, ethanol, 2-propanol, 2-methyl-1-propanol, 1-butanol, acetonitrile, acetone, dichloromethane, dioxane, or tetrahydrofuran, or combinations thereof, optionally including water.
  • In another aspect, a method is provided for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline solvate of Compound 1.
  • In another aspect, a method is provided for treating oxygen deficiency associated with sickle cell anemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline solvate of Compound 1.
    • EXAMPLES
  • The following examples describe the preparation, characterization, and properties of the free base of Compound 1 Form I ansolvate. Unless otherwise stated, all temperatures are in degrees Celcius (° C.) and the following abbreviations have the following definitions:
    • DSC Differential scanning calorimetry
    • DVS Dynamic vapor sorption
    • HPLC High performance liquid chromatography
    • NA Not applicable
    • ND Not determined
    • Q Percent dissolved per unit time
    • RH Relative humidity
    • RSD Residual standard deviation
    • RRT Relative retention time
    • SS-NMR Solid state nuclear magnetic resonance
    • TGA Thermogravimetric analysis
    • TG-IR Thermogravimetric infra red analysis
    • XRPD X-ray powder diffraction
    • VT-XRPD Variable temperature X-ray powder diffraction
    Synthetic Routes for Preparing Compound 1
  • The compound of formula (I) was synthesized as schematically described below and elaborated thereafter.
  • Figure US20160346263A1-20161201-C00003
    • Example 1 Synthesis of Compound 15
  • Figure US20160346263A1-20161201-C00004
  • To a solution of 2-bromobenzene-1,3-diol (5 g, 26.45 mmol) in DCM (50 ml) at 0° C. was added DIPEA (11.54 mL, 66.13 mmol) and MOMCl (4.42 mL, 58.19 mmol). The mixture was stirred at 0° C. for 1.5 h, and then warmed to room temperature. The solution was diluted with DCM, washed with sat. NaHCO3, brine, dried and concentrated to give crude product, which was purified by column (hexanes/EtOAc=4:1) to give desired product 15.58 g (90%).
    • Example 2 Synthesis of Compound 13 from 15
  • Figure US20160346263A1-20161201-C00005
  • To a solution of 2-bromo-1,3-bis(methoxymethoxy)benzene (15) (19.9 g, 71.8 mmol) in THF (150 mL) at −78° C. was added BuLi (2.5 M, 31.6 mL, 79.0 mmol) dropwise. The solution was stirred at −78° C. for 25 min (resulting white cloudy mixture), then it was warmed to 0° C. and stirred for 25 min. The reaction mixture slowly turns homogenous. To the solution was added DMF at 0° C. After 25 min, HPLC showed reaction completed. The mixture was quenched with sat. NH4Cl (150 mL), diluted with ether (300 mL). The organic layer was separated, aq layer was further extracted with ether (2×200 mL), and organic layer was combined, washed with brine, dried and concentrated to give crude product, which was triturated to give 14.6 g desired product. The filtrate was then concentrated and purified by column to give additional 0.7 g, total mass is 15.3 g.
    • Example 3 Synthesis of Compound 13 from Resorcinol 11
  • Figure US20160346263A1-20161201-C00006
  • A three-necked round-bottom flask equipped with mechanical stirrer was charged with 0.22 mol of NaH (50% suspension in mineral oil) under nitrogen atmosphere. NaH was washed with 2 portions (100 mL) of n-hexane and then with 300 mL of dry diethyl ether; then 80 mL of anhydrous DMF was added. Then 0.09 mol of resorcinol 11, dissolved in 100 mL of diethyl ether was added dropwise and the mixture was left under stirring at rt for 30 min. Then 0.18 mol of MOMCl was slowly added. After 1 h under stirring at rt, 250 mL of water was added and the organic layer was extracted with diethyl ether. The extracts were washed with brine, dried (Na2SO4), then concentrated to give the crude product that was purified by silica gel chromatography to give compound 12 (93% yield).
  • A three-necked round-bottom flask was charged with 110 mL of n-hexane, 0.79 mol of BuLi and 9.4 mL of tetramethylethylendiamine (TMEDA) under nitrogen atmosphere. The mixture was cooled at −10° C. and 0.079 mol of bis-phenyl ether 12 was slowly added. The resulting mixture was left under magnetic stirring at −10° C. for 2 h. Then the temperature was raised to 0° C. and 0.067 mol of DMF was added dropwise. After 1 h, aqueous HCl was added until the pH was acidic; the mixture was then extracted with ethyl ether. The combined extracts were washed with brine, dried (Na2SO4), and concentrated to give aldehyde 13 (84%).
  • 2,6-bis(methoxymethoxy)benzaldehyde (13): mp 58-59° C. (n-hexane); IR (KBr) n: 1685 (C═O) cm−1; 1H-NMR (400 MHz, CDCl3) δ 3.51 (s, 6H, 2 OCH3), 5.28 (s, 4H, 2 OCH2O), 6.84 (d, 2H, J=8.40 Hz, H-3, H-5), 7.41 (t, 1H, J=8.40 Hz, H-4), 10.55 (s, 1H, CHO); MS, m/e (relative intensity) 226 (M+, 3), 180 (4), 164 (14), 122 (2), 92 (2), 45 (100); Anal. Calc'd. for C11H14O5: C, 58.40; H, 6.24. Found: C, 57.98; H, 6.20.
    • Example 4 The Synthesis of Compound 16
  • Figure US20160346263A1-20161201-C00007
  • To a solution of 2,6-bis(methoxymethoxy)benzaldehyde (13) (15.3 g, 67.6 mmol) in THF (105 mL) (solvent was purged with N2) was added conc. HCl (12N, 7 mL) under N2, then it was further stirred under N2 for 1.5 h. To the solution was added brine (100 mL) and ether (150 ml). The organic layer was separated and the aqueous layer was further extracted with ether (2×200 mL). The organic layer was combined, washed with brine, dried and concentrated to give crude product, which was purified by column (300 g, hexanes/EtOAc=85:15) to give desired product 16 (9.9 g) as yellow liquid.
    • Example 5 Synthesis of Compound 17
  • Figure US20160346263A1-20161201-C00008
  • To a solution of 2-hydroxy-6-(methoxymethoxy)benzaldehyde (16) (10.88 g, 59.72 mmol) in DMF (120 mL) (DMF solution was purged with N2 for 10 min) was added K2CO3 (32.05 g, 231.92 mmol) and 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride (10) (15.78 g, 57.98 mmol). The mixture was heated at 65° C. for 1.5 h, cooled to rt, poured into ice water (800 mL). The precipitated solids were isolated by filtration, dried and concentrated to give desired product (17, 18 g).
    • Example 6 Synthesis of Compound (I)
  • Figure US20160346263A1-20161201-C00009
  • To a solution of 2-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-6-(methoxymethoxy)benzaldehyde (17) (18 g, 47.19 mmol) in THF (135 mL, solution was purged with N2) was added conc. HCl (12N, 20 mL). The solution was stirred at rt for 3 h when HPLC showed the reaction complete. The mixture was added to a solution of NaHCO3 (15 g) in water (1.2 L), and the resulting precipitate was collected by filtration, dried to give crude solid, which was further purified by column (DCM/EtOAc=60:40) to give pure product (15.3 g).
    • Example 7 Synthesis of Compound I (Free Base) and its HCl Salt Form
  • Compound (I) free base (40 g) was obtained from the coupling of the alcohol intermediate 7 and 2,6-dihydroxybenzaldedhye 9 under Mitsunobu conditions. A procedure is also provided below:
  • Figure US20160346263A1-20161201-C00010
    • Example 8 Synthesis of Compound (I) by Mitsunobu Coupling
  • Into a 2000-mL three neck round-bottom flask, which was purged and maintained with an inert atmosphere of nitrogen, was placed a solution of [2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methanol (7) (70 g, 322.18 mmol, 1.00 equiv) in tetrahydrofuran (1000 mL). 2,6-Dihydroxybenzaldehyde (9) (49.2 g, 356.21 mmol, 1.10 equiv) and PPh3 (101 g, 385.07 mmol, 1.20 equiv) were added to the reaction mixture. This was followed by the addition of a solution of DIAD (78.1 g, 386.23 mmol, 1.20 equiv) in tetrahydrofuran (200 ml) dropwise with stirring. The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 500 ml of H2O. The resulting solution was extracted with 3×500 ml of dichloromethane and the combined organic layers were dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with EA:PE (1:50-1:3) as eluent to yield the crude product. The crude product was re-crystallized from i-propanol/H2O in the ratio of 1/1.5. This resulted in 40 g (37%) of 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde as a light yellow solid. The compound exhibited a melting point of 80-82° C. MS (ES, m/z): 338.1 [M+1]. 1H NMR (300 MHz, DMSO-d6) δ 11.72 (s, 1H), 10.21 (s, 1H), 8.76 (d, J=3.6 Hz, 1H), 8.24 (d, J=2.7 Hz, 1H), 7.55 (m, 3H), 6.55 (m, 3H), 5.21 (s, 2H), 4.65 (m, 1H), 1.37 (d, J=5.1 Hz, 6H). 1H NMR (400 MHz, CDCl3) δ 11.96 (s, 1H), 10.40 (s, 1H), 8.77 (dd, J=4.8, 1.5 Hz, 1H), 8.00 (d, J=7.8 Hz, 1H), 7.63 (d, J=1.8 Hz, 1H), 7.49-7.34 (m, 2H), 6.59 (d, J=8.5 Hz, 1H), 6.37 (d, J=1.8 Hz, 1H), 6.29 (d, J=8.2 Hz, 1H), 5.10 (s, 2H), 4.67 (sep, J=6.7 Hz, 1H), 1.50 (d, J=6.6 Hz, 6H).
  • In another approach, multiple batches of Compound (I) free base are prepared in multi gram quantities (20 g). The advantage of this route is the use of mono-protected 2,6-dihydroxybenzaldehyde (16), which effectively eliminates the possibility of bis-alkylation side product. The mono-MOM ether of 2,6-dihydroxybenzaldehyde (16) can be obtained from two starting points, bromoresorcinol (14) or resorcinol (11) [procedures described in the Journal of Organic Chemistry, 74(11), 4311-4317; 2009]. All steps and procedures are provided below. Due to the presence of phenolic aldehyde group, precautions (i.e., carry out all reactions under inert gas such as nitrogen) should be taken to avoid oxidation of the phenol and/or aldehyde group.
  • Preparation of compound I HCl salt: A solution of compound I (55.79 g, 165.55 mmol) in acetonitrile (275 mL) was flushed with nitrogen for 10 min, then to this solution was added 3N aqueous HCl (62 mL) at room temperature. The mixture was stirred for additional 10 min after the addition, most of the acetonitrile (about 200 mL) was then removed by evaporation on a rotary evaporator at around 32° C., the remaining solution was frozen by cooling in an acetone-dry ice bath and lyophilized to afford compound I HCl salt (59.4 g).
    • Example 9 Characterization of the HCl Salt of Compound 1
  • Technique Details Result
    XRPD indexed HCl salt of Compound 1
    Microscope — pale yellow solids, thin blades/tablets,
    birefringent
    1H NMR DMSO-d6 consistent with structure, <0.01 moles MEK
    XRPD — HCl salt of Compound 1
    DVS — 0.03% gain upon equilibration at 5% RH
    0.10% gain from 5 to 95% RH
    0.09% loss from 95 to 5% RH
    post XRPD HCl I + Free Base Form I
    • Example 10 Physical Stability of the HCl Salt of Compound 1 Exposed to Water
  • Time (all times
    Condition are approximated) Observation XRPD Result
    contacted w/ — sheet formation after —
    water 5 min
    water slurry about 5 min Floating yellow Free base (FB)
    solids convert to I (indexed)
    white solids
    upon isolation
    vacuum dried about 1 day Remain FB I
    water slurry about 6 days white, thin blades, FB I + FB II
    birefringent (B)
    • Example 11 Physical Stability of the HCl Salt of Compound 1 with Grinding
  • Condition Time Observation XRPD Result
    grinding, dry 30 min off white/pale yellow HCl I
    grinding, wet 30 min off white/pale yellow paste HCl I + FB I
    • Example 12 Physical Stability of the HCl Salt of Compound 1 Exposed to Elevated Temperature and/or Vacuum
  • Condition Time Observation XRPD Result
    RT vacuum
     6 days pale yellow, blades/plates, B HCl I + FB I
    30° C.  6 hrs pale yellow, blades/tablets, B HCl I
    12 hrs pale yellow, blades/tablets, B HCl I + FB I
    24 hrs pale yellow, blades/tablets, B HCl I + FB I
    40° C.  6 hrs pale yellow, blades/tablets, B HCl I + FB I
    12 hrs pale yellow, blades/tablets, B HCl I + FB I
    24 hrs pale yellow, blades/tablets, B HCl I + FB I
    40° C.  6 hrs pale yellow, blades/tablets, B HCl I + FB I
    vacuum
    12 hrs pale yellow, blades/tablets, B HCl I + FB I
    24 hrs pale yellow, blades/tablets, B HCl I + FB I
    60° C.  6 days pale yellow blades, B HCl I + FB I
    60° C.  6 days pale yellow, blades, B; HCl I + FB I +
    vacuum irregular residue other free base
    form
    100 to 20 min pH paper above sample HCl I + FB I +
    125° C. indicate acidic volatiles other free base
    form
    • Example 13 Generation of the Free Base of Compound 1 from the Disproportionation of the HCl Salt of Compound 1 in Water (the Starting Material is the HCl Salt of Compound 1)
  • Method Observation XRPD Result
    1. contacted with water 1. pale yellow, FB I
    2. sonicated wets poorly
    3. filtered and rinsed with water 2. white
    4. dried under N2 for 10 minutes 3. —
    5. vacuum RT, overnight 4. —
    5. —
    1. contacted with water 1. — FB I + other
    2. sonicated for 5 minutes 2. pale yellow, free base form
    3. slurried for 10 minutes turned white
    4. filtered, rinsed with water 3. —
    5. dried under N2 for 10 minutes 4. —
    6. vacuum RT, overnight 5. white
    7. stored in freezer 6. —
    7. —
    1. slurry in water, RT, 8 days; 1. thick white FB II
    seeded with FB II slurry
    2. filtered, rinsed with water 2. —
    3. vacuum RT, overnight 3. —
    2. sub sample of slurry 2. — FB II (indexed)
    3. rinsed with water 3. —
    • Example 14 Characterization Form I of the Free Base of Compound 1
  • Technique Details Result
    XRPD indexed Free Base Form I
    XRPD — Free Base Form I
    TGA 25 to 0.2% weight loss up to 100° C.
    350° C.
    DSC
    25 to endothermic event with onset near 97° C.
    350° C.
    Hot Stage 22.7° C. initial, fines, birefringent
    Microscopy 91.2° C. increase in particle size and birefringence
    94.2° C. increase in particle size and birefringence
    95.7° C. melt onset, larger particles from initial
    heating
    96.1° C. melt continuation
    96.3° C. melt complete, no crystallization upon
    melting
    68.7° C. fresh preparation, larger magnification
    91.1° C. increase in birefringence
    94.8° C. melt onset, larger particles, birefringent
    95.4° C. melt continuation
    95.9° C. only few crystals remain, cooled to 92.6° C.
    92.6° C. held for 2 to 3 minutes crystal growth to
    larger blades, - began heating
    96.3° C. complete melt
    1H NMR DMSO-d6 consistent with structure
    DVS — 0.02% loss upon equilibration at 5% RH
    0.22% gain from 5 to 95% RH
    0.22% loss from 95 to 5% RH
    post XRPD Free Base Form I + other Free Base Material
    • Example 15 Characterization of Form II of the Free Base of Compound 1
  • Technique Details Result
    XRPD indexed Free Base Form II
    XRPD initial Free Base Form II
    after 7 days Free Base Form II
    TGA
    25 to 350° C. 0.1% weight loss up to 100° C.
    DSC
    25 to 350° C. endothermic event with onset near 97° C.
    1H NMR DMSO-d6 consistent with structure
    • Example 16 Characterization of Material N of the Free Base of Compound 1
  • Technique Details Result
    XRPD — Free Base Material N
    TGA
    25 to 350° C. 0.2% weight loss up to 100° C.
    DSC
    25 to 350° C. endothermic event with onset near 94° C.
    1H NMR DMSO-d6 consistent with structure, no residual reaction
    solvent observed
    • Example 17 Competitive Interconversion Slurries Between Free Base Forms I and II
  • Conditions Solvent Observation XRPD Result
    6° C., 6 days water white FB II
    6° C., 6 days heptane white FB II
    6° C., 6 days IPE faint pale yellow FB N
    RT, 6 days water white FB II
    RT, 6 days heptane off white FB II
    RT, 6 days IPE pale yellow FB NError! Bookmark not defined.
    RT, 6 days toluene pale yellow FB N
    57° C., 2 days water fines, off white, B FB II + FB I
    57° C., heptane blades and FB II
    overnight tablets, B
    57° C., IPE blades, laminated, FB II
    overnight pale yellow, B
    • Example 18 Competitive Interconversion Slurries Between Free Base Form II and Material N
  • Conditions
    35° C., 3 days heptane pale yellow fines, B FB N
    57° C., 3 days heptane larger blades, and rosettes of blades, B FB II
    • Example 19 Selected Experimental Methods
  • Indexing:
  • XRPD patterns are indexed by using proprietary SSCI software. Agreement between the allowed peak positions, marked with red bars within the figures, and the observed peaks indicates a consistent unit cell determination. Indexing and structure refinement are computational studies which are performed under the “Procedures for SSCI Non-cGMP Activities.” To confirm the tentative indexing solution, the molecular packing motifs within the crystallographic unit cells must be determined. No attempts at molecular packing were performed.
  • Differential Scanning Calorimetry (DSC):
  • DSC was performed using a TA Instruments Q2000 differential scanning calorimeter. Temperature calibration was performed using NIST-traceable indium metal. The sample was placed into an aluminum DSC pan, covered with a lid, and the weight was accurately recorded. A weighed aluminum pan configured as the sample pan was placed on the reference side of the cell. The data acquisition parameters and pan configuration for each thermogram are displayed in the image in the Data section of this report. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., −30-250-10 means “from −30° C. to 250° C., at 10° C./min”. The following summarizes the abbreviations used in each image for pan configurations: Tzero crimped pan (TOC); and Lid not crimped (NC).
  • Dynamic Vapor Sorption (DVS):
  • Dynamic vapor sorption (DVS) data were collected on a VTI SGA-100 Vapor Sorption Analyzer. NaCl and PVP were used as calibration standards. Samples were not dried prior to analysis. Adsorption and desorption data were collected over a range from 5 to 95% RH at 10% RH increments under a nitrogen purge. The equilibrium criterion used for analysis was less than 0.0100% weight change in 5 minutes with a maximum equilibration time of 3 hours. Data were not corrected for the initial moisture content of the samples.
    • Microscopy
  • Hot Stage Microscopy:
  • Hot stage microscopy was performed using a Linkam hot stage (FTIR 600) mounted on a Leica DM LP microscope equipped with a SPOT Insight™ color digital camera. Temperature calibrations were performed using USP melting point standards. Samples were placed on a cover glass, and a second cover glass was placed on top of the sample. As the stage was heated, each sample was visually observed using a 20×0.40 N.A. long working distance objective with crossed polarizers and a first order red compensator. Images were captured using SPOT software (v. 4.5.9).
  • Polarized Light Microscopy:
  • During the course of experimentation generated samples were viewed utilizing a microscope with cross polarized light to observe morphology and birefringence. Samples were visually observed at 40× magnification.
  • 1H Solution Nuclear Magnetic Resonance (1H NMR)
  • SSCI:
  • Samples were prepared for NMR spectroscopy as ˜5-50 mg solutions in the appropriate deuterated solvent. The specific acquisition parameters are listed on the plot of the first full spectrum of each sample in the data section for samples run at SSCI.
  • Spectral Data Solutions:
  • For samples run using Spectral Data Solutions (subcontractor), the solution 1H NMR spectra were acquired at ambient temperature on a Varian UNITYINOVA-400 spectrometer (1H Larmor Frequency=399.8 MHz). The specific acquisition parameters are listed on the spectral data sheet and on each data plot of the spectrum of the sample.
    • Thermogravimetric Analysis (TGA)
  • TG analyses were performed using a TA Instruments 2950 thermogravimetric analyzer. Temperature calibration was performed using nickel and Alumel™. Each sample was placed in an aluminum pan and inserted into the TG furnace. The furnace was heated under a nitrogen purge. The data acquisition parameters are displayed above each thermogram in the Data section of this report. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., 25-350-10 means “from 25° C. to 350° C., at 10° C./min”. The use of 0 as the initial temperature indicates sample run initiated from ambient.
    • XRPD Analysis
  • INEL:
  • XRPD patterns were collected with an Inel XRG-3000 diffractometer. An incident beam of Cu Kα radiation was produced using a fine-focus tube and a parabolically graded multilayer mirror. Prior to the analysis, a silicon standard (NIST SRM 640d) was analyzed to verify the Si 111 peak position. A specimen of the sample was packed into a thin-walled glass capillary, and a beam-stop was used to minimize the background from air. Diffraction patterns were collected in transmission geometry using Windif v. 6.6 software and a curved position-sensitive Equinox detector with a 2θ range of 120°. The data-acquisition parameters for each pattern are displayed above the image in the Data section of this report.
  • PANalytical Transmission:
  • XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation produced using an Optix long, fine-focus source. An elliptically graded multilayer mirror was used to focus Cu Kα X-rays through the specimen and onto the detector. Prior to the analysis, a silicon specimen (NIST SRM 640d) was analyzed to verify the Si 111 peak position. A specimen of the sample was sandwiched between 3 μm thick films and analyzed in transmission geometry. A beam-stop, short antiscatter extension, and an antiscatter knife edge were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the specimen and Data Collector software v. 2.2b. The data-acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) before the mirror and the incident-beam antiscatter slit (SS).
  • PANalytical Reflection:
  • XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu Kα radiation produced using a long, fine-focus source and a nickel filter. The diffractometer was configured using the symmetric Bragg-Brentano geometry. Prior to the analysis, a silicon specimen (NIST SRM 640d) was analyzed to verify the observed position of the Si 111 peak is consistent with the NIST-certified position. A specimen of the sample was prepared as a thin, circular layer centered on a silicon zero-background substrate. Antiscatter slits (SS) were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the sample and Data Collector software v. 2.2b. The data acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) and the incident-beam SS.
  • Approximate Solubility:
  • A weighed sample was treated with aliquots of the test solvent at room temperature. The mixture was sonicated between additions to facilitate dissolution. Complete dissolution of the test material was determined by visual inspection. Solubility was estimated based on the total solvent used to provide complete dissolution. Some samples were then heated and observed visually for complete dissolution. The actual solubility may be greater than the value calculated because of the use of solvent aliquots that were too large or due to a slow rate of dissolution. The solubility is expressed as “less than” if dissolution did not occur during the experiment. If complete dissolution was achieved as a result of only one aliquot addition, the solubility is expressed as “greater than”.
  • Anti-Solvent Additions: Compound 1/organic solvent solutions were contacted with solvents that Compound 1 was determined to be poorly soluble or insoluble in. These anti solvent additions were added to help lower the solubility of the solvent system and induce crystallization.
  • Cooling and Slow Cools:
  • Solutions were prepared in the selected solvent or solvent/anti-solvent system. These solutions were chilled below room temperature within a refrigerator for varying lengths of time in an attempt to induce nucleation. The presence or absence of solids was noted. Upon observation of solids, in quantities sufficient for analysis, isolation of material was conduction. If insufficient quantities were present further cooling was performed in a freezer. Samples were either isolated for analysis wet or as dry powders.
  • Compression:
  • Selected samples were compressed utilizing a KBr die and a Carver hydraulic press. An applied load of 10000 lbs was applied to the die shaft for approximately 20 minutes.
  • Crystallization from Solution:
  • Saturated solutions were generated at ambient and then capped. Nucleation was observed to occur from these systems during evaluation of the Free Base of Compound 1.
  • Fast Evaporation:
  • Solutions were prepared in selected solvents and agitated between aliquot additions to assist in dissolution. Once a mixture reached complete dissolution, as judged by visual observation, the solution was allowed to evaporate at ambient temperature in an uncapped vial or at ambient under nitrogen. The solids that formed were isolated for evaluation.
  • Milling:
  • Selected material was milled utilizing a Reitch Mill. The material was loaded into an agate lined milling vessel followed by the addition of an agate ball. The vessel was then placed on to the mill and milled for approximately 30 minutes at frequency of 1/30 seconds. The milling was stopped approximately every 10 minutes and material scraped from the wall before further milling.
  • Slurry:
  • Solutions were prepared by adding enough solids to a given solvent so that excess solids were present. The mixture was then agitated in a sealed vial at either ambient or an elevated temperature. After a given amount of time, the solids were isolated for analysis.
  • Temperature and Relative Humidity Stress:
  • Selected materials were stressed at elevated related humidity and/or temperature. Relative humidity jars (saturated salt solutions used to generate desired relative humidity) were utilized to store selected samples. The following relative humidity jars were utilized during evaluation: 75% RH (NaCl) and 60% (NaBr), to investigate the effects of humidity. Temperatures utilized were ambient, 30, 40, 60, and 100-125° C.
  • Vacuum:
  • Selected materials were stressed under reduced pressure for a set time period. Initial stressing was conducted with the in-house vacuum system with absolute pressure readings <500 mTorr, typically 30 to 50 mTorr (0.030 to 0.05 mm Hg). Additional vacuum stressing was conducted at 48 mmHg utilizing a portable lab vacuum and bleed to simulate conditions similar to those expected during process.
    • Example 20 Disproportionation of the HCl Salt
  • The disproportionation of the HCl salt in water was utilized to generate free base. The nucleation of Free Base Form I occurs first. Extending the slurry time induces the transformation to a more thermodynamically stable phase relative to Form I, Free Base Form II.
  • Three anhydrous materials of the free base were identified; Free Base Forms I, II, and Material N. Free Base Material N appears to be most stable form, relative to Forms I and II, at room temperature. Free Base Material N is enantiotropic relative to Form II, and will transform reversibly at a specific transition temperature (estimated near 42° C.). Above the transition temperature, Free Base Form II appears to be the most stable form, relative to Form I and Material N.
  • The HCl salt (termed “HCl Form I”) was subjected to various stress conditions and monitored by XRPD to evaluate physical stability. As discussed, disproportionation occurred during the DVS experiment of the HCl salt, indicating instability upon exposure to elevated humidity. Disproportionation is further evident with wet milling or in direct contact with water (e.g. slurry) as shown by the presence of Free Base Forms I or II, identified by XRPD. The volatilization and loss of HCl upon heating and/or vacuum is shown by the presence of Free Base Form I, identified by XRPD, and also indicates instability at these conditions.
      • Contact with water resulted in a visual color change of the material from pale yellow to white; physical changes were also observed microscopically. Immediate disproportionation occurs. XRPD analysis identified the resulting material from a water slurry (˜5 minutes) as Free Base Form I. Free Base Form II also becomes evident if the amount of time in the slurry is extended.
      • The volatilization of HCl was evident within hours of exposure to drying conditions. Conversion to Free Base Form I was observed by XRPD at 30° C. (after 12 hrs), 40° C. (after 6 hrs), and at 40° C./48 mmHg (after 6 hrs).
      • Free Base Material C becomes evident at more extreme conditions involving elevated temperatures. Heating HCl Form I up to 125° C. induces the loss of acidic volatiles (judged visually by use of pH paper held above sample). XRPD analysis identifies the resulting sample as a mixture of HCl Form I, Free Base Form I, and Free Base Material C. Exposing the HCl salt to 60° C. under vacuum for 6 days provides the same result. The nature of Material C is not established
  • The HCl salt was shown to disproportionate immediately in water. This phenomenon was utilized to generate free base. The nucleation of Free Base Form I occurs first. Extending the slurry time induces the transformation to a more thermodynamically stable phase relative to Form I, Free Base Form II.
      • A 20 ml vial was charged with 266.4 mg of HCl Form I and contacted with 10 ml of water. The sample was sonicated until the pale yellow material changed color to white. The resulting solids were collected by filtration (water aspirated) and rinsed with 10 ml of water. A nitrogen purge was blown over the sample for approximately 10 minutes prior to exposure to vacuum at ambient temperature to dry overnight. The resulting material was analyzed by XRPD and determined to be Free Base Form I.
      • A 250 ml Erlenmeyer flask was charged with 6.0250 grams of HCl Form I and contacted with 220 mL of water. The sample was sonicated for approximately 5 minutes to disperse the material. The yellow material changed color to white during sonication. A stir bar was added and the sample was stirred at 700 RPM for approximately 10 minutes. The solids were collected by filtration and rinsed with 220 ml of water followed by a nitrogen purge over the sample for approximately 10 minutes prior to exposure to vacuum at ambient temperature. The sample was dried at this condition for approximately 24 hours yielding 5.1834 grams of material. The resulting material was analyzed by XRPD and determined to be a mixture of Free Base Form I and Free Base Material D. (The nature of Material D is not established.)
  • The procedure used to generate Free Base Form II is described below.
      • A 20 ml vial was charged with 477.5 mg of HCl Form I lot 20 and contacted with 20 ml of water. The sample was sonicated until the pale yellow material changed color to white. A small amount of sample (mixture of Free Base Forms I and II) was added as seeds. A stir bar was added and the sample was stirred at 200 RPM for 8 days. The resulting solids were collected by filtration (water aspirated) and rinsed with 15 ml of water. The sample was exposed to vacuum at ambient temperature to dry overnight. The resulting material was analyzed by XRPD and determined to be Free Base Form II.
    Example 21 Additional Procedures for the Preparation of the Free Base of Form I, Form II, and From N Conversion of the Free Base of Compound 1 to the HCl Salt
  • General Procedure:
  • Slowly treat a solution of the free base of Compound 1 in MEK (5 vol) with cone HCl (1.5 eq). Cool the resulting slurry to 0-5° C. for 1 h and filter. Wash solids with MEK (1 vol). Dry under vacuum at 30-35° C.
  • Preparation A:
  • Following the general procedure above, 35 g of crude Compound 1 was processed to provide the HCl salt as a pale yellow solid (32.4 g, 82% yield, 99.8% purity by HPLC).
  • Preparation of the Free Base Form I from the HCl Salt of Compound 1
  • General Procedure:
  • Vigorously stir a slurry of the HCl salt of Compound 1 in DIW (10 vol) for 5 min to 2 h. Filter the slurry, wash with DIW (2×1 vol), dry on funnel, then further dry under vacuum at 30-35° C.
  • Preparation A:
  • Following the general procedure above, after stirring for 1 h, 32 g of the HCl salt of Compound 1 was processed to provide the free base as a pale yellow solid (27.3 g, 95% yield, 99.8% purity by HPLC; DSC indicates Form I).
  • Preparation B:
  • Following the general procedure above, after stirring for 1 h, 39 g of the HCl salt of Compound 1 was processed to provide the free base as a pale yellow solid (31.8 g, 90% yield, >99.9% purity by HPLC)).
  • Preparation C:
  • Thus, the HCl salt of Compound 1 (134 g) was vigorously stirred in water (10 vol) until the material appeared as a finely dispersed white slurry. After filtration and drying, a white crystalline solid (116 g, 96% recovery, >99.9% purity by HPLC) was isolated.
  • Preparation D:
  • The purpose of this experiment was to prepare the free base from Compound 1, HCl. Thus, the HCl salt of Compound 1 (65.3 g) was vigorously stirred in water (10 vol) until the material appeared as a finely dispersed white slurry. After filtration and drying, a white crystalline solid (57.5 g, 97.6% recovery, >99.9% purity by HPLC) was isolated.
  • Preparation of GBT000440 Free Base Form II from GBT000440 Free Base Form I
  • General Procedure:
  • Stir a slurry of the free base of Compound 1 Form I in an appreciate solvent (e.g. heptane or water) (10 vol) for 1-7 days. Filter the slurry, wash with DIW (2×1 vol), dry on funnel, then further dry under vacuum at 30-35° C.
  • Preparation A:
  • Thus, the free base of Compound 1, Form I (114 g) was stirred in n-heptane (10 vol) at 35° C. After 4 days, XRPD indicated the material was Form II. The slurry was filtered and dried to provide 110 g off white solid.
  • Preparation B:
  • the free base of Compound 1 (5 g) was slurried in heptanes (10 vol 50 mlL) at room temperature. After 4 days, the slurry was filtered to provide an off-white solid.
  • Preparation C:
  • the free base of Compound 1 (5.8 kg) was slurried in heptanes (10 vol) at room temperature. After 2 days, the slurry was filtered and washed with 2×2 vol n-heptane to provide 4.745 kg of Form II as an off-white solid.
  • Preparation D:
  • the free base of Compound 1 (5 g) was slurried in water. After 4 days, the slurry was filtered to provide an off-white solid. Preparation of GBT000440 free base Form N from GBT000440 free base Form I or Form II
  • General Procedure:
  • Stir a slurry of the free base of Compound 1, Form I in MTBE (4 vol) at room temperature for at least 4 days. After 4 days, filter the slurry to provide an off-white solid. Obtain XRPD to confirm polymorph as Material N.
  • Preparation A:
  • Following the general procedure above, 27 g of the free base of Compound 1, Form I (48TRS079) was stirred in MTBE at 18-23° C. for 4 days. DSC indicated it should be Material N. Isolated 22.2 g cream colored solid (82% recovery, 99.9 purity by HPLC). XRPD analysis planned.
  • Preparation B:
  • Following the general procedure above, 31 g of the free base of Compound 1, Form I was stirred in 3 vol MTBE at 18-23° C. for 4 days.
  • Preparation C:
  • the free base of Compound 1, Form I (13KWB023, 1 g) was slurried in MTBE (5 vol) at room temperature. Slurry was seeded with Material N (50 mg). After 4 days, the slurry was filtered to provide a off-white solid. DSC indicated the melting point was the same as Material N.
  • Preparation D:
  • The purpose of this experiment was to convert the free base of Compound 1, Form II to Material N. Thus, the free base of Compound 1 (0.5 g) was stirred in 5 vol of di-n-propyl ether at 18-23° C. After 2 days, DSC corresponded to the pattern observed for Material N. XRPD analysis confirmed Material N had been formed.
  • Preparation E:
  • To the free base of Compound 1, Form II (5 g) was added diisopropyl ether (5 vol, 25 mL) at room temperature. After 4 days, the slurry was filtered to provide a off-white solid. DSC indicates Material N.
    • Example 22 Preliminary Solvent-Based Screens
  • Rapid, solvent-based screens were conducted in an attempt to determine the most stable form of the free base of Compound 1. The study also provides a preliminary assessment of the propensity of these materials to exist in various crystal forms. Generated solids were observed by polarized light microscopy (PLM) and/or analyzed by X-ray powder diffraction (XRPD), comparing the resulting XRPD patterns to known patterns of Compound 1.
  • If possible, XRPD patterns were indexed. Indexing is the process of determining the size and shape of the crystallographic unit cell given the peak positions in a diffraction pattern. The term gets its name from the assignment of Miller index labels to individual peaks. XRPD indexing serves several purposes. If all of the peaks in a pattern are indexed by a single unit cell, this is strong evidence that the sample contains a single crystalline phase. Given the indexing solution, the unit cell volume may be calculated directly and can be useful to determine their solvation states. Indexing is also a robust description of a crystalline form and provides a concise summary of all available peak positions for that phase at a particular thermodynamic state point.
  • Materials exhibiting unique crystalline XRPD patterns, based on visual inspection of peaks associated with these materials, were given letter designations. The letter designation is tentatively associated with the word ‘Material’ if insufficient characterization data is available. The nomenclature is used only to aid in the identification of unique XRPD patterns and does not imply that the stoichiometry, crystalline phase purity, or chemical purity of the material is known. Materials are further designated as forms with Roman numeral designations (i.e., Free Base Material A=Free Base Form I), when phase purity (obtained through indexing of the XRPD pattern or single crystal structure elucidation) and chemical identity/purity (obtained through proton NMR spectroscopy) of the material is determined.
  • Three anhydrous materials were identified: Forms I, II, and Material N. Material N appears to be most stable form, relative to Forms I and II, at room temperature. Material N is enantiotropic relative to Form II, and will transform reversibly at a specific transition temperature (estimated near 42° C.). Above the transition temperature, Form II appears to be the most stable form, relative to Form I and Material N.
  • Materials C and D are used to identify a few additional, low intensity peaks observed in XRPD patterns which were predominantly composed of the Free Base Form I of Compound 1 or mixtures of the HCl Form I and Free Base Form I of Compound 1.
    • Example 23 Anhydrous Ansolvate Forms Form I
  • Free Base Form I is a metastable, anhydrous phase of the free base that is formed immediately from the disproportionation of the HCl salt in water. A representative XRPD pattern of Form I was successfully indexed and the unit cell volume is consistent with anhydrous free base. Visual comparison of the XRPD pattern to the historical pattern of the free base provided indicates the material may be similar; however, the historical pattern appears to exhibit additional peaks from a potential mixture.
  • The 1H NMR spectrum is consistent with the chemical structure of Compound 1. The chemical shift at approximately 2.5 ppm is assigned to DMSO (due to residual protons in the NMR solvent). Peaks that could be associated with residual solvents were not visible, consistent with the anhydrous unit cell volume determined from the indexing solution above and the negligible wt % loss observed by TGA discussed below.
  • Thermograms (TG) data shows negligible weight loss, 0.2%, up to 100° C., consistent with an anhydrous form. The DSC exhibits a single endotherm with an onset near 97° C. (similar to what is observed for Form II). The endotherm is consistent with a melt by hot stage microscopy. However, changes in particle size and birefringence were evident prior to the melt; a possible phase change occurred. Consequently, if a phase change occurred and an endotherm similar to that of Free Base Form II was observed, it can be inferred that the observed melt is truly not of Form I but of the resulting phase, most likely Form II.
  • The DVS isotherm indicates Form I is not hygroscopic. Negligible weight gain and loss, 0.2%, was observed through sorption/desorption. By XRPD, the material recovered from the DVS experiment was predominately Free Base Form I with a few additional peaks. The additional peaks were termed Free Base Material D. The nature of Material D is unknown; however, the appearance of another phase(s) indicates that Form I is not likely physically stable at elevated humidity conditions (at ambient temperature).
    • Form II
  • Free Base Form II is an anhydrous phase of the free base. Form II is enantiotropically related to Material N, where it is the thermodynamically stable form above an estimated transition temperature of 42° C. Form II can be generated in solvents that do not form known solvates; such as heptane, IPE, MTBE, or toluene; through short-term slurry conversions of Form I (where the crystallization kinetics delay the nucleation of the more stable form) or elevated temperature slurries (above 42° C.). A representative XRPD pattern of Form II was successfully indexed and the unit cell volume is consistent with anhydrous free base of Compound 1.
  • The 1H NMR spectrum is consistent with the chemical structure of Compound 1. The chemical shift at approximately 2.5 ppm is assigned to DMSO (due to residual protons in the NMR solvent). Peaks that could be associated with residual solvents were not visible, consistent with the anhydrous unit cell volume determined from the indexing solution above and the negligible wt % loss observed by TGA discussed below.
  • Thermograms (TG) data show negligible weight loss, 0.1%, up to 100° C., consistent with an anhydrous form. The DSC exhibits a single endotherm (80.1 J/g) with an onset near 97° C.
  • Form II remained unchanged after 7 days at ambient storage, through reanalysis by XRPD. The form is known to be thermodynamically metastable, relative to Material N, at this condition; however, the kinetics of polymorph conversion may be slow at ambient conditions in the solid state.
    • Material N
  • Free Base Material N is an anhydrous phase of the free base. Material N is enantiotropically related to Form II, where it is the thermodynamically stable form below an estimated transition temperature of 42° C. Given the opportunity, Material N can be generated through slurries in solvents that do not form known solvates; such as heptane, IPE, MTBE, or toluene; at temperatures below 42° C. The following is an example of a laboratory scale procedure used to generate Free Base Material N.
      • 53.0 mg of Free Base Form I was contacted with 2 ml of an IPE/free base solution (concentration 13 mg/ml). A stir bar was added and the sample was slurried for 7 days at ambient. The solution was decanted from the sample and the remaining solids briefly dried under nitrogen. Characterization Data indicates Material N is a unique crystalline phase.
  • The 1H NMR spectrum is consistent with the chemical structure of Compound 1. The chemical shift at approximately 2.5 ppm is assigned to DMSO (due to residual protons in the NMR solvent). Peaks that could be associated with residual solvents were not visible, consistent with the negligible wt % loss observed by TGA discussed below.
  • Thermograms (TG) data show negligible weight loss, 0.2%, up to 100° C., consistent with an anhydrous form. The DSC exhibits a single endotherm (82.8 J/g) with an onset at 94° C.
  • Tentative Determination of the Thermodynamic Relationship between Free Base Forms I, II, and Material N
  • Characterization data indicates that Forms I, II, and Material N are unique crystalline phases; however, only the XRPD patterns of Forms I and II were successfully indexed to confirm phase purity. Therefore, any proposed thermodynamic relationship between these materials is a working hypothesis, where the phase purity of Material N is assumed.
  • Phase transitions of solids can be thermodynamically reversible or irreversible. Crystalline forms which transform reversibly at a specific transition temperature (Tp) are called enantiotropic polymorphs. If the crystalline forms are not interconvertable under these conditions, the system is monotropic (one thermodynamically stable form). Several rules have been developed to predict the relative thermodynamic stability of polymorphs and whether the relationship between the polymorphs is enantiotropic or monotropic. The heat of fusion rule is applied within this study. The heat of fusion rule states that if the higher melting form has the lower heat of fusion then the two forms are enantiotropic, otherwise they are monotropic.
  • Material N appears to be most stable form, relative to Forms I and II, at room temperature. Based on the heats of fusion and melts determined by DSC, Material N is enantiotropic relative to Form II, and will transform reversibly at a specific transition temperature (TN-II). Due to a possible phase change of Form I to Form II that occurred prior to the observed endotherm in the DSC, the relationship of Form I with either Material N or Form II cannot be conclusively determined through the heat of fusion rule. However, through various interconversion slurries, it was shown that Form I is the least thermodynamically stable form between 6° C. and TN-II. In addition, assuming that Form I spontaneously converted to Form II in the DSC at elevated temperatures (prior to the observed melt), it must follow that Form II is also more stable than Form I above TN-II.
    • Example 24 Estimated Transition Temperature
  • The estimated transition temperature between two enantiotropically related forms can be calculated from their melt onsets and heats of fusion based on the equation shown below.
  • T p = Δ H f , 2 - Δ H f , 1 + ( C p , liq - C p , 1 ) · ( T f , 1 - T f , 2 ) Δ H f , 2 T f , 2 - Δ H f , 1 T f , 1 + ( C p , liq - C p , 1 ) · ln ( T f , 1 T f , 2 ) Where , ( C p , liq - C p , 1 ) = k · Δ H f , 1 and k = 0.005
  • Between Material N and Form II, the equation estimates a transition temperature of 42° C. To summarize, the relative stability of the forms from most to least stable is shown below.
  • Temperature Relative
    Range* Stability Comments
    Below 6° C. N > II Relationships to Form I are not
    established below this temp
    Between 6° C. and N > II > I —
    TN-II
    Above TN-II (II > N) and Relationship between Form
    (II > I) I and Material N is not
    established above this temp
    *TN-II is estimated to be near 42° C.
    • Example 25 Energy-Temperature Diagram
  • The Energy-Temperature Diagram of FIG. 17 is a semi-quantitative graphical solution of the Gibbs-Helmholtz equation, where the enthalpy (H) and free energy (G) isobars for each form are depicted as a function of temperature.
    • Example 26 Competitive Interconversion Slurry Experiments
  • Interconversion experiments were performed to support the thermodynamic relationship between polymorphs illustrated by the Energy-Temperature Diagram above. Interconversion or competitive slurry experiments are a solution-mediated process that provides a pathway for the less soluble (more stable) crystal to grow at the expense of the more soluble crystal form. Outside the formation of a solvate or degradation, the resulting more stable polymorph from an interconversion experiment is contemplated to be independent of the solvent used because the more thermodynamically stable polymorph has a lower energy and therefore lower solubility. The choice of solvent affects the kinetics of polymorph conversion and not the thermodynamic relationship between polymorphic forms.
  • The results of the interconversion studies are consistent with the tentative Energy-Temperature Diagram shown herein. Binary slurries were prepared at ambient, 6, and 57° C. using Forms I and II. Form II resulted from the majority of these experiments, confirming that Form II is more stable relative to Form I within this temperature range.
  • A few of the experiments conducted at ambient and 6° C. resulted in Material N. Although this does not provide specific clarification between Forms I and II, it does provide evidence that Material N is the most stable form relative to both Forms I and II at these temperatures (which were conducted below the estimated transition temperature of 42° C.). Additional interconversion slurries between Form II and Material N were conducted at temperatures which bracket this estimated transition temperature and confirm that Form II and Material N are enantiotropically related.
    • Example 27 Solid-State Nuclear Magnetic Resonance
  • 13C and 15N spectra acquired for the three polymorphic forms I, II and Material N. See FIGS. 10 and 11. Spectra were acquired at 253K to prevent any low temperature transitions occurring during measurement and acquisition parameters optimised for each polymorphic form.
  • Based on solid-state nuclear magnetic resonance, all three forms are crystalline and are distinct polymorphic forms. Form I contains one molecule per asymmetric unit, Form II contains two molecules per asymmetric unit and Form N contains four molecules per asymmetric unit. See the 15N spectra in FIG. 11.
    • Example 28 Chemical and Physical Stability Evaluation of the Free Base Form I of Compound 1
  • A mixture predominately composed of Free Base Form I (with Free Base Material D) were exposed to stability conditions to assess physical and chemical stability. Three conditions were used; open to 25° C./60% RH, open to 40° C./75% RH, and closed to 60° C. Physical stability was evaluated by XRPD. Chemical stability was determined through UPLC and 1H NMR, when applicable. Materials were tested after 1, 7, and 14 days of exposure.
    • Chemical Stability of Free Base Form I
  • For the free base stability sample, UPLC showed very low levels of impurities present. The level of impurities did not rise significantly after 14 days of age. This would seem to indicate good chemical stability against the conditions used for stability assessment. The 1H NMR spectra of samples exposed to 60° C. (14 days) were also consistent with this conclusion.
    • Physical Stability of Free Base Form I
  • The free base of Compound 1 remained unchanged, by XRPD, at 25° C./60% RH. However, differences were observed at the other two conditions. The few, minor peaks attributed to Free Base Material D were no longer observed, indicating that Material D is metastable and is not sustained at elevated temperatures. In addition, Free Base Form II was observed after 7 days of age. This is consistent with the conclusions discussed herein, where Free Base Form II is more stable relative to Free Base Form I at these temperatures.
    • Example 29 Physical Stability Evaluation of the Free Base Form II and Material N (Form N) of Compound 1
  • DSC was modulated at low underlying heating rate, followed by X-ray powder diffraction. A low underlying heating rate was used of 0.02° C. mid′. The temperature was 80° C. for form N and 90° C. for form II. Exposure was essentially isothermal, covering a temperature range with sensitivity to detect changes in physical form. The resultant materials were examined by X-ray powder diffraction. No changes in physical form were observed for either polymorphic form II or polymorphic form N (i.e., material N).
  • Forms II and N were exposed to 40° C./75% relative humidity (RH), 80° C., 80° C./80% RH for 9 days followed by X-ray powder diffraction. No changes in physical form were observed for either polymorphic form II or polymorphic form N.
  • The thermodynamic barrier for inter-conversion between polymorphic form II and form N is high, and physical stability is good for both forms. Thermally induced inter-conversion between form II and form N is unlikely to occur.
    • Example 30 The Relative Thermodynamic Stability of Polymorphic Forms II and N
  • Extended solvent mediated maturation studies were conducted with 1:1 w/w mixtures of polymorphic form II and form N. Hexane provided a good medium for solvent assessments. The temperatures used include −20° C., −10° C., 0° C., 10° C., 20° C., 30° C., 40° C. and 50° C. Significantly increased solubility was observed at 30° C., 40° C. and 50° C. Solids derived from maturation at −20° C., −10° C., 0° C., 10° C., 20° C. were analyzed by X-ray powder diffraction. In each case, significant conversion to Form N was observed.
  • Form N is thermodynamically more stable than form II at temperatures of 20° C. and lower. An enantiotropic relationship between the two forms is likely to exhibit equivalence in thermodynamic stability at ca. 30-40° C.
    • Example 31 Morphology of Form N
  • Initial examination of a batch of polymorphic form N indicates an acicular morphology.
  • While this invention has been described in conjunction with specific embodiments and examples, it will be apparent to a person of ordinary skill in the art, having regard to that skill and this disclosure, that equivalents of the specifically disclosed materials and methods will also be applicable to this invention; and such equivalents are intended to be included within the following claims.

Claims (39)

1.-20. (canceled)
21. A method of increasing oxygen affinity of hemoglobin S in a patient in need thereof comprising administering to the patient in need thereof a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00011
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
22. The method of claim 21, wherein the crystalline ansolvate is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
23. The method of claim 21, wherein the crystalline ansolvate is characterized by at least three powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
24. The method of claim 21, wherein the crystalline ansolvate is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
25. The method of claim 21, wherein the crystalline ansolvate is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5.
26. The method of claim 21, wherein the crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1.
27. The method of claim 21, wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
28. A method of increasing oxygen affinity of hemoglobin S in a patient in need thereof comprising administering to the patient in need thereof a pharmaceutical composition comprising a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00012
and at least one pharmaceutically acceptable excipient, wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
29. The method of claim 28, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
30. The method of claim 28, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
31. The method of claim 28, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
32. The method of claim 28, wherein the crystalline ansolvate of the pharmaceutical composition of Compound 1 is substantially free of a solvated polymorph of Compound 1.
33. The method of claim 28, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
34. A method of treating sickle cell disease in a patient having sickle cell disease comprising administering to the patient in need thereof a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00013
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
35. The method of claim 34, wherein the crystalline ansolvate is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
36. The method of claim 34, wherein the crystalline ansolvate is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
37. The method of claim 34, wherein the crystalline ansolvate is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
38. The method of claim 34, wherein the crystalline ansolvate is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5.
39. The method of claim 34, wherein the crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1.
40. The method of claim 34, wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
41. A method of treating sickle cell disease in a patient having sickle cell disease comprising administering to the patient in need thereof a pharmaceutical composition comprising a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00014
and at least one pharmaceutically acceptable excipient, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
42. The method of claim 41, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
43. The method of claim 41, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
44. The method of claim 41, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
45. The method of claim 41, wherein the crystalline ansolvate of the pharmaceutical composition is substantially free of a solvated polymorph of Compound 1.
46. The method of claim 41, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
47. A method of treating pulmonary disorder in a patient having a pulmonary disorder comprising administering to the patient in need thereof a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00015
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
48. The method of claim 47, wherein the crystalline ansolvate is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
49. The method of claim 47, wherein the crystalline ansolvate is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
50. The method of claim 47, wherein the crystalline ansolvate is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
51. The method of claim 47, wherein the crystalline ansolvate is substantially free of a solvated polymorph of Compound 1.
52. The method of claim 47, wherein the crystalline ansolvate is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
53. A method of treating pulmonary disorder in a patient having a pulmonary disorder comprising administering to the patient in need thereof a pharmaceutical composition comprising a crystalline ansolvate of Compound 1:
Figure US20160346263A1-20161201-C00016
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
54. The method of claim 53, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
55. The method of claim 53, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
56. The method of claim 53, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ).
57. The method of claim 53, wherein the crystalline ansolvate of the pharmaceutical composition is substantially free of a solvated polymorph of Compound 1.
58. The method of claim 53, wherein the crystalline ansolvate of the pharmaceutical composition is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2°2θ), and less than about 25 mole %, 10 mole %, or 5 mole % of one or more of crystalline Form I, Material N, or amorphous forms of Compound 1.
US15/236,283 2014-02-07 2016-08-12 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Abandoned US20160346263A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/236,283 US20160346263A1 (en) 2014-02-07 2016-08-12 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US15/801,152 US10137118B2 (en) 2014-02-07 2017-11-01 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/163,942 US10722502B2 (en) 2014-02-07 2018-10-18 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/923,498 US11452720B2 (en) 2014-02-07 2020-07-08 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US17/885,238 US20220395492A1 (en) 2014-02-07 2022-08-10 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461937404P 2014-02-07 2014-02-07
US201461937393P 2014-02-07 2014-02-07
US14/616,548 US9447071B2 (en) 2014-02-07 2015-02-06 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US15/236,283 US20160346263A1 (en) 2014-02-07 2016-08-12 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/616,548 Continuation US9447071B2 (en) 2014-02-07 2015-02-06 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/801,152 Continuation US10137118B2 (en) 2014-02-07 2017-11-01 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Publications (1)

Publication Number Publication Date
US20160346263A1 true US20160346263A1 (en) 2016-12-01

Family

ID=53774359

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/616,548 Active US9447071B2 (en) 2014-02-07 2015-02-06 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US15/236,283 Abandoned US20160346263A1 (en) 2014-02-07 2016-08-12 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US15/801,152 Active US10137118B2 (en) 2014-02-07 2017-11-01 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/163,942 Active US10722502B2 (en) 2014-02-07 2018-10-18 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/923,498 Active US11452720B2 (en) 2014-02-07 2020-07-08 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US17/885,238 Pending US20220395492A1 (en) 2014-02-07 2022-08-10 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/616,548 Active US9447071B2 (en) 2014-02-07 2015-02-06 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Family Applications After (4)

Application Number Title Priority Date Filing Date
US15/801,152 Active US10137118B2 (en) 2014-02-07 2017-11-01 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/163,942 Active US10722502B2 (en) 2014-02-07 2018-10-18 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US16/923,498 Active US11452720B2 (en) 2014-02-07 2020-07-08 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US17/885,238 Pending US20220395492A1 (en) 2014-02-07 2022-08-10 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Country Status (28)

Country Link
US (6) US9447071B2 (en)
EP (2) EP3102208B1 (en)
JP (4) JP6809681B2 (en)
KR (2) KR102345380B1 (en)
CN (4) CN114213390A (en)
AP (1) AP2016009261A0 (en)
AU (3) AU2015214182B2 (en)
CA (1) CA2916564C (en)
CY (1) CY1124097T1 (en)
DK (1) DK3102208T3 (en)
EA (1) EA028529B1 (en)
ES (1) ES2860648T3 (en)
HR (1) HRP20210388T1 (en)
HU (1) HUE053706T2 (en)
IL (2) IL243214B (en)
LT (1) LT3102208T (en)
MX (2) MX361810B (en)
MY (1) MY189995A (en)
NZ (1) NZ715029A (en)
PE (2) PE20160179A1 (en)
PL (1) PL3102208T3 (en)
PT (1) PT3102208T (en)
RS (1) RS61653B1 (en)
SA (1) SA516370358B1 (en)
SG (4) SG10201911668VA (en)
SI (1) SI3102208T1 (en)
TW (4) TWI755952B (en)
WO (1) WO2015120133A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US10017491B2 (en) 2013-03-15 2018-07-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10034879B2 (en) 2011-12-28 2018-07-31 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10100040B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10137118B2 (en) 2014-02-07 2018-11-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10315991B2 (en) 2013-03-15 2019-06-11 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10377741B2 (en) 2011-12-28 2019-08-13 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10683285B2 (en) 2018-11-19 2020-06-16 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
US10787430B2 (en) 2016-06-17 2020-09-29 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
CN106227475A (en) * 2016-07-18 2016-12-14 重庆市中迪医疗信息科技股份有限公司 Print system and method thereof
WO2019104062A1 (en) * 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2020127924A1 (en) * 2018-12-21 2020-06-25 Bionice, S.L.U. Process and intermediates for the preparation of voxelotor
EP3693364A1 (en) 2019-02-11 2020-08-12 Sandoz Ag Crystalline salts of a hemoglobin s allosteric modulator
JP7312317B2 (en) * 2019-09-12 2023-07-20 アシムケム ラボラトリーズ （フーシン） カンパニー リミテッド Continuous production apparatus for 2,6-dihydroxybenzaldehyde and its use
BR112022009522A2 (en) 2019-11-19 2022-08-16 Global Blood Therapeutics Inc VOXELOTOR ADMINISTRATION METHODS
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
EP3888750A1 (en) 2020-04-02 2021-10-06 Sandoz AG Crystalline form of voxelotor
IT202000009970A1 (en) 2020-05-05 2021-11-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF SICKLE CELL ANEMIA
WO2021224280A1 (en) 2020-05-05 2021-11-11 Dipharma Francis S.R.L. Synthesis of a sickle cell disease agent and intermediates thereof
EP3939589A1 (en) 2020-07-15 2022-01-19 Sandoz Ag High drug load tablet comprising voxelotor
WO2022013052A1 (en) 2020-07-15 2022-01-20 Sandoz Ag Compounds comprising voxelotor and 2,5-dihydroxybenzoic acid and crystal forms
CN112047924B (en) * 2020-10-10 2023-04-18 山东汇海医药化工有限公司 Preparation method of Wo Keluo polypeptide
JP2023548293A (en) 2020-11-06 2023-11-16 グローバル ブラッド セラピューティクス インコーポレイテッド Method for the preparation of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AU2021398051A1 (en) * 2020-12-10 2023-07-27 Genzyme Corporation Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2022249200A1 (en) * 2021-05-25 2022-12-01 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridine-3-yl) methoxy)benzaldehyde
WO2023081801A2 (en) 2021-11-05 2023-05-11 Global Blood Therapeutics, Inc. Methods of administering voxelotor
WO2023199345A1 (en) * 2022-04-14 2023-10-19 Msn Laboratories Private Limited, R&D Center Novel solid state forms of voxelotor and their preparation methods thereof
CN115636742B (en) * 2022-11-11 2024-04-09 江西亚太科技发展有限公司 Recrystallization method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US9447071B2 (en) * 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL218146A (en) 1956-02-13 1900-01-01
BE787580A (en) 1971-08-13 1973-02-14 Hoechst Ag FURANNE DERIVATIVE PREPARATION PROCESS
BE787576A (en) 1971-08-13 1973-02-14 Hoechst Ag BENZOFURANE DERIVATIVES AND THEIR USE AS OPTICAL BLASTERS
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
DE2853765A1 (en) 1978-12-13 1980-06-26 Bayer Ag METHOD FOR PRODUCING BENZIMIDAZOLYLBENZOFURANES
DE2904829A1 (en) 1979-02-08 1980-08-14 Bayer Ag METHOD FOR PRODUCING BENZIMIDAZOLYLBENZOFURANE
IT1133025B (en) 1979-06-29 1986-07-09 Wellcome Found NEW ETHERS FOR PHARMACEUTICAL USE AND PROCEDURE FOR THEIR PREPARATION
DE3175083D1 (en) 1980-12-18 1986-09-11 Wellcome Found Pharmaceutical compounds, their preparation and use
JPS5929667A (en) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (en) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd Hydroquinone derivative
DE3431004A1 (en) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt NEW 3-PYRIDYL COMPOUNDS AND METHOD FOR THEIR PRODUCTION
DD226590A1 (en) 1984-09-07 1985-08-28 Univ Leipzig MEANS FOR PHAGENHEMMUNG IN MICROBIAL PRODUCTION PROCESSES
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (en) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, MEDICINE CONTAINING SUCH DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF THE DERIVATIVES
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
DD258226A1 (en) 1987-03-05 1988-07-13 Fahlberg List Veb PROCESS FOR PRODUCING AROXYMETHYLCHINOXALINES
JPH07121937B2 (en) 1987-03-18 1995-12-25 大塚製薬株式会社 Carbostyril derivative
JPS63258463A (en) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd 2-phenoxypyrimidine derivative and herbicide
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (en) 1988-01-27 1997-09-03 サントリー株式会社 Pyrrolitidine compounds and uses thereof
JPH01305081A (en) 1988-04-04 1989-12-08 E R Squibb & Sons Inc 3-acylamino-1-((((substituted sulfonyl)amino) carbonyl)amino)-2-azetinones
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
DD276480A1 (en) 1988-10-26 1990-02-28 Fahlberg List Veb PROCESS FOR THE PREPARATION OF NAPHTHO / 2,1-B / FUR-2-YLCHINOXALINES
DD276479A1 (en) 1988-10-26 1990-02-28 Fahlberg List Veb PROCESS FOR THE PREPARATION OF BENZO / B / FUR-2-YLCHINOXALINES
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (en) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 ALCHYLYLPHENOLS SUBSTITUTED FOR ANTI-INFLAMMATORY ACTION, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
AU641769B2 (en) 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0487745A4 (en) 1990-06-19 1993-01-20 Meiji Seika Kabushiki Kaisha Pyridine derivative with angiotensin ii antagonism
NL9001752A (en) 1990-08-02 1992-03-02 Cedona Pharm Bv NEW 1,4-DIHYDROPYRIDINE DERIVATIVES.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
JPH05301872A (en) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd Picolinic acid derivativee and herbicide
EP0498380A1 (en) 1991-02-08 1992-08-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Complexing agents
JPH0641118A (en) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd Picolinic acid derivative and herbicide
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (en) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 Thiazolyl benzofuran derivative
FR2680512B1 (en) 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994001406A1 (en) 1992-07-01 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Contrast agents for mr diagnosis
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
AU668818B2 (en) 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
DE4318550A1 (en) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Arylidene-4-oxo-2-thioxo-3-thiazolidinecarboxylic acids, process for their preparation and pharmaceutical compositions containing them
IL110151A (en) 1993-06-30 1998-10-30 Sankyo Co Amide derivatives and pharmaceutical compositions containing them
JPH0725882A (en) 1993-07-07 1995-01-27 Res Dev Corp Of Japan Intermediate for production of acromelic acid b and e and its production
DE69418789T2 (en) 1993-08-05 1999-12-02 Hoechst Marion Roussel Inc 2- (Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl) benzofuran-7-carbamate derivatives, their preparation and use as acetylcholinesterase inhibitors
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (en) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazin derivatives, process for their preparation and their use as 5-dipoxygenase and cyclooxygenase inhibitors
DK0750631T3 (en) 1994-02-14 2000-10-23 Merrell Pharma Inc Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo [c] azepine-3-ondisulfide derivatives as enkephalinase and ACE inhibitors
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (en) 1994-11-25 1996-05-30 Hoechst Ag Heterospiro compounds and their use as electroluminescent materials
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (en) 1996-05-17 2007-03-22 興和株式会社 Chalcone derivative and pharmaceutical containing the same
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
WO1998008818A1 (en) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
AR010061A1 (en) 1996-11-12 2000-05-17 Garcia Cattebeke Cybele Carina DERIVED FROM 3- (2-PIRIDIL) -PYZAZOL SUBSTITUTED, A PROCESS FOR ITS PREPARATION, INTERMEDIATE COMPOUNDS, A HERBICIDAL COMPOSITION AND INHIBITOR OF THE GROWTH OF PLANTS, A METHOD TO CONTROL AND INHIBIT THE GROWTH OF THE PLANTS AND THE COMPOSITION
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
BR9815170A (en) 1997-12-12 2000-10-10 Euro Celtique S A Luxembourg "method of obtaining compound applicable in the treatment of asthma in mammals"
HUP0100156A3 (en) 1998-02-25 2002-12-28 Genetics Inst Inc Cambridge Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
HUP0104421A3 (en) 1998-12-14 2003-05-28 Hoffmann La Roche Phenylglycine derivatives
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
EP1150957A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
ES2203443T3 (en) 1999-03-31 2004-04-16 Basf Aktiengesellschaft SUBSTITUTED ANILINE COMPOUNDS.
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
MXPA01011502A (en) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Enzyme-activated anti-tumor prodrug compounds.
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
CA2376676C (en) 1999-06-28 2009-01-20 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
ES2252063T3 (en) 1999-09-28 2006-05-16 Eisai Co., Ltd. QUINUCLIDINE COMPOUND AND MEDICINAL PRODUCT THAT INCLUDES THE COMPOUND AS AN ACTIVE PRINCIPLE.
CZ20021570A3 (en) 1999-11-05 2002-10-16 Emisphere Technologies, Inc. Phenylamincarboxylic acids and compositions for delivering active agents
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
DK1103545T3 (en) 1999-11-29 2004-03-15 Hoffmann La Roche 2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-N- (6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl) -isobutyramide
CZ20022332A3 (en) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
IL153834A0 (en) 2000-07-14 2003-07-31 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
WO2002009723A2 (en) 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (en) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
DE60142355D1 (en) 2000-11-20 2010-07-22 Biovitrum Ab Publ PIPERAZINYLPYRAZIN COMPOUNDS AS AGONISTS OR ANTAGONISTS ON THE SEROTONIN 5HT-2 RECEPTOR
JPWO2002051849A1 (en) 2000-12-26 2004-04-22 第一製薬株式会社 Cdk4 activity inhibitor
WO2002053547A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
GB0102595D0 (en) 2001-02-01 2001-03-21 Virk Kuldip Smart solar
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
CA2452159A1 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (en) 2001-08-31 2003-03-12 Konica Corp Silver halide color photographic sensitive material, color photographic sensitive material, image forming method for the same and method for creating digital image information
KR100467313B1 (en) 2001-11-22 2005-01-24 한국전자통신연구원 Red organic electroluminescent compounds, method for synthesizing the same and electroluminescent devices
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
RU2296758C2 (en) 2002-08-08 2007-04-10 Смитклайн Бичем Корпорейшн Derivatives of thiophene
TW200420542A (en) 2002-08-23 2004-10-16 Kirin Brewery A compound having TGF β inhibition activity and a medicinal composition containing the same
US7368578B2 (en) 2002-09-10 2008-05-06 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
ES2372047T3 (en) 2002-12-04 2012-01-13 Virginia Commonwealth University ANTIDREPANOCÍTIC AGENTS.
US20040181075A1 (en) 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US7655633B2 (en) 2002-12-25 2010-02-02 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
WO2004073675A1 (en) 2003-02-24 2004-09-02 Randolph Riemschneider Cosmetic composition with a whitening effect, method for the production and use thereof
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
AU2004247319A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
EP2314576A1 (en) 2003-11-05 2011-04-27 F.Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists
JP2007513082A (en) 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Benzyl ether amine compounds useful as CCR-5 antagonists
KR20110116225A (en) 2003-12-02 2011-10-25 셀진 코포레이션 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
AU2005211349A1 (en) 2004-01-30 2005-08-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
WO2005086951A2 (en) 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
DE102004015226B3 (en) 2004-03-24 2005-08-25 Siemens Ag Plasma cleaning method suitable for interior surfaces of e.g. bulbs for discharge lamps, forms back pressure and ignites plasma only inside bulb
CA2563752A1 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
WO2006003923A1 (en) 2004-06-30 2006-01-12 Sankyo Company, Limited Substituted benzene compound
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2585165A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab Substituted aminopyridines and uses thereof
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2006088173A1 (en) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
EA200702020A1 (en) 2005-03-19 2008-02-28 Эморпасифик Корпорейшн NEW COMPOUNDS, THEIR ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS AS ANTAGONISTS OF VANILLOID RECEPTORS AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd Antifungal agent containing pyridine derivative
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
PL2465580T3 (en) 2005-04-28 2014-05-30 Viiv Healthcare Co Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity
DE102005025989A1 (en) 2005-06-07 2007-01-11 Bayer Cropscience Ag carboxamides
JP2006342115A (en) 2005-06-10 2006-12-21 Shionogi & Co Ltd Polycyclic compound having hiv integrase inhibition activity
US20100063081A1 (en) 2005-06-30 2010-03-11 Stuart Edward Bradly CPCR Agonists
CN100562514C (en) 2005-07-22 2009-11-25 中国科学院上海药物研究所 Substituted propion amide derivatives, Preparation Method And The Use
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
CN101360731B (en) 2005-10-11 2013-01-30 联邦高等教育系统-匹兹堡大学 Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins
EP1950212B1 (en) 2005-10-27 2016-02-24 Shionogi Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007084914A2 (en) 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
RU2318818C1 (en) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (en) 2006-07-26 2008-01-30 中国海洋大学 Dioxygen piperazidine compounds and preparation method and usage thereof
AR063211A1 (en) 2006-07-27 2009-01-14 Amorepacific Corp DERIVATIVES OF 3- (PIRIDIN-3-IL) ACRILAMIDE AND 3- (PIRIDIN-3-IL) PROPIONAMIDE, A METHOD FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ASSOCIATED DISEASES WITH THE VANILOID RECEIVER.
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (en) 2006-08-21 2013-03-21 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
ES2670407T3 (en) 2006-09-03 2018-05-30 Techfields Biochem Co. Ltd Positively charged water-soluble acetaminophen prodrugs and compounds related to a very fast skin penetration rate
JP2010505811A (en) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク Pyrido [4,3-d] pyrimidin-4 (3H) -one derivatives as calcium receptor antagonists
EA200970401A1 (en) 2006-10-23 2009-10-30 Мерк Энд Ко., Инк. 2- [1-PHENYL-5-HYDROXY OR METHOXI-4-ALPHA-METHYLHEXHYDROCYCLOPENT [f] INDAZOL-5-IL] ETHYLPHENYL DERIVATIVES AS GLAND-CORTICOID RECEPTOR
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
FR2909379B1 (en) 2006-11-30 2009-01-16 Servier Lab NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
JP5246779B2 (en) 2006-11-30 2013-07-24 国立大学法人東京工業大学 New curcumin derivatives
RU2532135C2 (en) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Iminopyridine derivatives and use thereof as microbiocides
TWI407960B (en) 2007-03-23 2013-09-11 Jerini Ag Small molecule bradykinin b2 receptor modulators
US7994367B2 (en) 2007-05-22 2011-08-09 Sumitomo Chemical Company, Limited Method for producing benzaldehyde compound
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
ES2423181T3 (en) 2007-07-17 2013-09-18 F. Hoffmann-La Roche Ag 11ß-hydroxysteroid dehydrogenase inhibitors
EP2183027B1 (en) 2007-07-26 2011-08-31 Novartis AG Organic compounds
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
PL2212323T3 (en) 2007-10-17 2013-01-31 Novartis Ag Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (en) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd Pharmaceutical composition containing benzyl phenyl glucopyranoside derivative
US8258349B2 (en) 2008-02-14 2012-09-04 Suitomo Chemical Company, Limited Process for production of benzaldehyde compound
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
BRPI0906348A2 (en) 2008-04-11 2019-07-16 Inst Of Medicinal Molecular Designer Inc compound represented by formula (1), pharmaceutical composition; pai-1 inhibitor and prevention drug for prevention and / or therapeutic treatment of disease caused by the manifestation of pai-1 or increased action of pai-1
JP2011136906A (en) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd Heterocyclic compound
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
JP5436544B2 (en) 2008-05-08 2014-03-05 ノヴァ サウスイースタン ユニバーシティ− Inhibitors specific for vascular endothelial growth factor receptor
CA2726742A1 (en) 2008-06-04 2009-12-10 Brent Stranix Hiv integrase inhibitors from pyridoxine
DE102008027574A1 (en) 2008-06-10 2009-12-17 Merck Patent Gmbh New pyrrolidine derivatives as MetAP-2 inhibitors
JP5314330B2 (en) 2008-06-16 2013-10-16 住友化学株式会社 Process for producing 2- (aryloxymethyl) benzaldehyde and its intermediate
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (en) 2008-09-22 2010-10-28 Jerini Ag MODULATORS OF THE BRADIQUININE B2 RECEPTOR OF SMALL MOLECULA
JP2012508692A (en) 2008-11-12 2012-04-12 シェーリング コーポレイション Inhibitors of fatty acid binding protein (FABP)
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
CN104107176A (en) 2009-03-31 2014-10-22 利亘制药公司 Oral formulations of diphenylsulfonamide endothelin and angiotensin II receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010129055A1 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
US8486965B2 (en) 2009-08-26 2013-07-16 Takeda Pharmaceutical Company Limited Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
CN102498100A (en) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 Heterocyclic antiviral compounds
EP3566697A1 (en) 2009-11-09 2019-11-13 Wyeth LLC Tablet formulations of neratinib maleate
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (en) 2010-04-26 2017-01-23 광주과학기술원 Novel pyridine carboxylic acid compound as a P2X1 and P2X3 receptor antagonist, the preparation method thereof and a composition containing the same
CN102232949A (en) 2010-04-27 2011-11-09 孙远 Drug dissolution increasing composition and preparation method thereof
TWI535442B (en) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
CN103003283A (en) * 2010-06-09 2013-03-27 Abbvie公司 Crystalline forms of kinase inhibitors
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (en) 2010-09-28 2013-08-28 上海大学 Method for screening dihydrochalcone compound
EA028217B1 (en) 2010-12-27 2017-10-31 Такеда Фармасьютикал Компани Лимитед Orally disintegrating tablet (variants)
CA2832570A1 (en) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
EP2698368B1 (en) 2011-04-11 2018-02-14 Green Tech Co., Ltd. Novel pyrazole derivative
CN102952062B (en) 2011-08-12 2016-06-08 中国医学科学院医药生物技术研究所 Replace benzo-heterocycle compound and its preparation method and application
PE20142353A1 (en) * 2011-09-15 2015-01-10 Demerx Inc NORIBOGAINE SALT ANSOLVATES
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
DK3141542T3 (en) * 2011-12-28 2020-08-10 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and methods for their use in increasing tissue siltation
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015015216B1 (en) 2012-12-27 2020-01-07 Sumitomo Chemical Company, Limited TETRAZOLINONE COMPOUND, AGENT AND PLUG CONTROL METHOD
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902874C (en) 2013-03-15 2021-04-20 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-benzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201591426A1 (en) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
EP2970315B1 (en) 2013-03-15 2021-09-15 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150256A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
PE20151900A1 (en) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc COMPOUNDS AND THEIR USES TO MODULATE HEMOGLOBIN
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20160206604A1 (en) 2013-08-26 2016-07-21 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
TWI544395B (en) 2014-09-26 2016-08-01 義隆電子股份有限公司 Scanning method and device of single layer capacitive touch panel
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (en) 2016-05-12 2023-12-11 美商全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1hpyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
ES2966707T3 (en) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Hemoglobin modulators for the treatment of sickle cell disease
SI3880654T1 (en) 2018-11-19 2022-04-29 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US9447071B2 (en) * 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Bonaventura et al., "Molecular Controls, etc.," Antioxidants & Redox Signaling, 18(17), 2013, 2298-2313. *
CMU Pharmaceutical polymorphism, internet p. 1-3 (2002) printout 4/3/08. *
Concise Encyclopedia Chemistry, NY: Walter de Gruyter, 1993, 872-873. *
Deem, "Red Blood Cells, etc.," Advances in experimental medicine and biology, (2006) 588, 217-231. *
Doelker, english translation of Ann. Pharm. Fr., 2002, 60: 161-176, pages 1-39. *
Doelker, english translation of S.T.P, Pratiques (1999), 9(5), 399-409, pages 1033. *
Huckauf et al., "Oxygen Affinity, etc.," Bull. europ. Physiopath. resp., 1976, 12, 129-142. *
Jain et al., "Polymorphism in Pharmacy", Indian Drugs, 1986, 23(6) 315-329. *
Muzaffar et al., "Polymorphism and Drug Availability, etc.," J of Pharm. (Lahore), 1979, 1(1), 59-66. *
Otuska et al., "Effect of Polymorphic, etc.," Chem. Pharm. Bull., 47(6) 852-856 (1999). *
Singhal et al., "Drug Polymorphism, etc.," Advanced Drug Delivery reviews 56, p. 335-347 (2004). *
Taday et al., "Using Terahertz, etc.," J of Pharm. Sci., 92(4), 2003, 831-838. *
U.S. Pharmacopia #23, National Formulary #18, 1995, 1843-1844. *
Vichinsky, "Emerging 'A' therapies, etc.," Hematology 2012, 271-275. *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806733B2 (en) 2011-12-28 2020-10-20 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10822326B2 (en) 2011-12-28 2020-11-03 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10377741B2 (en) 2011-12-28 2019-08-13 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10034879B2 (en) 2011-12-28 2018-07-31 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10100040B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10315991B2 (en) 2013-03-15 2019-06-11 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10017491B2 (en) 2013-03-15 2018-07-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10435393B2 (en) 2013-03-15 2019-10-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10858317B2 (en) 2013-03-15 2020-12-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10829470B2 (en) 2013-03-15 2020-11-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11530191B2 (en) 2013-03-15 2022-12-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10137118B2 (en) 2014-02-07 2018-11-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10722502B2 (en) 2014-02-07 2020-07-28 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11452720B2 (en) 2014-02-07 2022-09-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10695330B2 (en) 2015-03-30 2020-06-30 Global Blood Therapeutics, Inc. Methods of treatment
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11944612B2 (en) 2015-12-04 2024-04-02 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10577345B2 (en) 2016-05-12 2020-03-03 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US10683285B2 (en) 2018-11-19 2020-06-16 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US11548880B2 (en) 2018-11-19 2023-01-10 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Also Published As

Publication number Publication date
TW202003489A (en) 2020-01-16
NZ715029A (en) 2021-07-30
KR20160118204A (en) 2016-10-11
US20210161876A1 (en) 2021-06-03
SG10201804139VA (en) 2018-06-28
HUE053706T2 (en) 2021-07-28
AU2022203213A1 (en) 2022-06-02
CA2916564C (en) 2023-02-28
US20150225366A1 (en) 2015-08-13
PE20201444A1 (en) 2020-12-10
US10722502B2 (en) 2020-07-28
AU2015214182A1 (en) 2016-01-21
TWI670265B (en) 2019-09-01
CN114181195A (en) 2022-03-15
EP3102208A4 (en) 2017-06-14
TW202134227A (en) 2021-09-16
MX2015017614A (en) 2016-04-07
ES2860648T3 (en) 2021-10-05
TWI714182B (en) 2020-12-21
AU2020207778B2 (en) 2022-02-17
IL243214B (en) 2021-09-30
SA516370358B1 (en) 2017-12-21
US20190255031A1 (en) 2019-08-22
TWI755952B (en) 2022-02-21
CA2916564A1 (en) 2015-08-13
AU2020207778A1 (en) 2020-08-06
PE20160179A1 (en) 2016-05-20
SG11201510135XA (en) 2016-01-28
SG10201911662YA (en) 2020-02-27
KR102588476B1 (en) 2023-10-11
BR112015032160A8 (en) 2020-01-14
CN114181194A (en) 2022-03-15
KR102345380B1 (en) 2021-12-29
SG10201911668VA (en) 2020-01-30
EA201592212A8 (en) 2016-07-29
AP2016009261A0 (en) 2016-06-30
DK3102208T3 (en) 2021-03-08
HRP20210388T1 (en) 2021-04-16
JP2017505347A (en) 2017-02-16
IL243214A0 (en) 2016-02-29
EA028529B1 (en) 2017-11-30
TW202245761A (en) 2022-12-01
JP2021113225A (en) 2021-08-05
EP3102208A1 (en) 2016-12-14
MX2022007912A (en) 2022-07-21
US10137118B2 (en) 2018-11-27
CY1124097T1 (en) 2022-05-27
TWI799115B (en) 2023-04-11
TW201612171A (en) 2016-04-01
JP7444957B2 (en) 2024-03-06
WO2015120133A1 (en) 2015-08-13
LT3102208T (en) 2021-05-10
SI3102208T1 (en) 2021-07-30
IL285918A (en) 2021-10-31
JP2023016994A (en) 2023-02-02
US11452720B2 (en) 2022-09-27
CN114213390A (en) 2022-03-22
EA201592212A1 (en) 2016-05-31
US9447071B2 (en) 2016-09-20
CN105431147A (en) 2016-03-23
AU2015214182B2 (en) 2020-04-30
MX361810B (en) 2018-12-14
PL3102208T3 (en) 2021-07-19
EP3868745A1 (en) 2021-08-25
US20180289686A1 (en) 2018-10-11
PT3102208T (en) 2021-04-05
KR20220002722A (en) 2022-01-06
US20220395492A1 (en) 2022-12-15
RS61653B1 (en) 2021-04-29
BR112015032160A2 (en) 2017-07-25
JP2019137699A (en) 2019-08-22
JP6809681B2 (en) 2021-01-06
EP3102208B1 (en) 2021-01-13
MY189995A (en) 2022-03-22

Similar Documents

Publication Publication Date Title
US11452720B2 (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US20160207904A1 (en) Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA034409B1 (en) Methods of making crystalline l-ornithine phenyl acetate
JP2020519654A (en) Berberine ursodeoxycholic acid solid form and compositions and methods thereof
OA17658A (en) Crystalline polymorphs of the free base of 2hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin3-yl)methoxy)benzaldehyde.
EA040317B1 (en) CRYSTALLINE POLYMORPHIC FORMS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
BR112015032160B1 (en) CRYSTALLINE ANSOLVATE OF COMPOUND, COMPOSITION AND PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMRI SSCI, LLC, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARENT, STEPHAN D.;HOUSTON, TRAVIS;REEL/FRAME:042533/0376

Effective date: 20160613

Owner name: GLOBAL BLOOD THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMRI SSCI, LLC;REEL/FRAME:042533/0383

Effective date: 20160614

AS Assignment

Owner name: GLOBAL BLOOD THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LI, ZHE;REEL/FRAME:043156/0716

Effective date: 20150219

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION